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ABSTRACT
Trypsin inhibitory activity from the hemolymph of the tobacco
hornworm, Manduca sexta, was pur ified by affini ty chromatography on
immobilized trypsin and resolved into two fractions with molecular
weights of 13700 (inhibitor A) and 8000 (inhibitor B) by Sephadex G-
gel filtration. SDS-polyacrylamide gel electrophoresis under non-
reducing conditions gave a molecular weight estimate of 15000 for
inhibitor A and 8500 for inhibitor B. Electrophoresis of these inhib-
itors under reducing conditions on polyacrylamide gels gave molecular
weight estimates of 8300 and 9100 for inhibitor A and inhibitor B,
respectively, suggesting that inhibitor A is a dimer. Isoelectro-
focusing on polyacrylamide gels focused inhibitor A as a single band
with pI of 5. 7, whereas inhibitor B was resolved into two components
with pIs of 5. 3 and 7. Both inhibitors A and B are stable at 1000 C
and at pH 1. 0 for at least 30 minutes, but both are inactivated by
dithiothreitol even at room temperature and non-denaturing conditions.
Inhibitors A and B inhibit trypsin, chymotrypsin, plasmin, and
thrombin but they do not inhibit elastase, papain, pepsin, subtilisin
BPN' and thermolysin. In fact, subtilisin BPN' completely inactivated
both inhibitors A and B. Inhibitor A and inhibitor B form stable
complexes with trypsin. Stoichiometric studies showed that inhibitor A
combines with trypsin and chymotrypsin in a 1:1 molar ratio.
inhibition constants (Ki) for trypsin and chymotrypsin inhibition by
inhibitor A were estimated to be 1. 45 x 10-8 M and 1. 7 x 10-8 M,
respectively. Inhibi tor A in complex with chymotrypsin does not
inhibit trypsin (and vice versa) suggesting that inhibitor A has a
commn binding site for trypsin and chymotrypsin. The amino terminal
amino acid sequences of inhibitors A and B revealed that both these
inhibitors are homologous to the bovine pancreatic trypsin inhibitor
(Kuni tz) .
Quantitation of the trypsin inhibitory activity in the hemolymph
of the larval and the pupal stages of Manduca sexta showed that the
trypsin inhibitory activity decreased from larval to the pupal stage.
Further, inhibitor A at the concentration tested caused approximately
50% reduction in the rate of proteolytic activation of prophenoloxidase
in a hemocyte lysate preparation from Manduca sexta , suggesting that
inhibitor A may be involved in the regulation of prophenoloxidase
activation. However, inhibitor B was not effective even at three times
the concentration of inhibitor A. Since activation of prophenoloxidase
has been suggested to resemble the activation of alternative pathway of
complement, the effect of inhibitors A and B and the hemolymph of
Manduca sexta on human serum alternative pathway complement activity
was evaluated. The results showed that, although inhibitors A and B do
not affect human serum alternative complement pathway, other
oteinaceous component (s) in Manduca sexta hemolymph interact (s) and
cause (s) an inhibition of human serum alternative complement pathway
when tested using rabbit erythrocyte hemolytic assay.
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CHAPTER I
INTRODUCTION
Objectives and Significance
The class Insecta is the largest group of animals on earth and
consists of a population which is larger than all other animal groups
combined. Insects, as a group, have a large impact on mankind, both
medically and agr icul tur ally. Some insects such as the cotton boll
weevil and the army worm cause considerable agr icultural damage, while
many other insects such as the mosquito and the tse-tse fly serve as
vectors of dreaded diseases such as encephalitis and sleeping sickness.
Thus, an understanding of the biochemistry of insects may provide in-
sights into effective methods of insect control.
A well known pest of the tobacco crops in the United States is the
larvae of the sphingid moth Manduca sexta. Until the large scale intro-
duct ion of chemical pesticides three decades ago, these larvae (referred
to as the hornworms) caused considerable economic damage especially to
the flue cured and wrapper tobacco by foraging on the leaves. Al though
successful control methods for preventing crop damage by hornworm
foraging have been developed, the tobacco hornworm has continued to be
used as an exper imental animal for studying the biochemistry and the
physiology of insects. Two factors have contributed to the popularity
of the tobacco hornworms as exper imental animals: first, they can be
grown on an artificial diet which allows controlled developmental
studies; secondly, the effect of environmental factors such as the
photoperiod and temperature on growth and development, and the develop-
mental control by insect hormones have been well descr ibed. Therefore,
this insect is a useful model to correlate biochemical and physiological
findings with developmental changes.
It is well recognized that proteolytic enzymes are involved in
important regulatory functions in both prokaryotic and in eukaryotic
organisms (1, 2, 3). Many of the physiologically significant processes
in insects also require proteolytic enzymes. For example,
metamorphosis in insects involves the catabolism of the tissues of one
stage of development and the reformation of the tissues at the next
stage. The catabolic steps dur ing metamorphosis require proteolytic
enzymes. In addition, the enzyme phenoloxidase, which plays a key role
in insect immunity, is activated from its precursor by limited
proteolysis, and the coagulation process in insects is also thought to
be activated by limited proteolysis.
Although the importance of proteases in insect physiology is well
known, the physiological regulation of insect proteases, particularly
the role of endogenous protease inhibitors in the control of protease
activity, are not well understoo. In an effort to understand the bio-
chemical function (s) of insect protease inhibitors, the hemolymph pro-
tease inhibitors from the tobacco hornworm, Manduca sexta, were
studied. This thesis reports the isolation, and physicochemical
character ization of two trypsin inhibitors present in the hemolymph of
the tobacco hornworm as a prelude to elucidation of their possible
physiological significance.
The Role of Proteases in Insect Physiology
proteases and insect development
The life cycle of holometabolous insects consists of three stages,
the larva, the pupa and the ad lt. Dur ing the pupal stage the larval
tissues are histolysed and the adult structures are developed from a
group of cells set aside for this purpose from the larval stage (for
example in Drosophila these cells are termed imaginal discs) . The
transformation of the larvae through pupae into the adult is under
rigorous hormonal control. Juvenile hormone (JH) is responsible for
the maintenance of larval structures while a steroid called ecdysone
stimulates the metamorphosis of the larvae into pupae and adults.
The larval stage of insects is subdivided into several instars.
During each successive ins tar the larvae grow bigger. At the end of
each ins tar the outer layer of the insect integument has to be shed
(molted) and a new larger layer synthesized in order to accommodate the
increase in size of the larva. Dur ing the molting process the old
cuticle is digested by a battery of enzymes which includes proteases
and chi tinases, and the digested mater ial is reabsorbed while the
undigested matter is shed as exuvia. Two proteases have been inden-
tified from the malting fluid of the silkworm Antheraea polyphemus (4).
These enzymes have molecular weights of 30, 000 daltons and 34, 000
daltons and are inhibited by diisopropylphosphofluor idate (DFP), an
irreversible inhibitor of serine proteases. Both proteases hydrolyse
benzoyl-L-arginine ethyl ester and tosyl-L-arginine methyl ester and,
therefore, have trypsin-like specificity. These proteases also are
inhibi ted by soybean trypsin inhibi tor; however, the effect of insect
. .
c.:ji.'
----
protease inhibitors on these proteases have not been explored.
trypsin-like protease has also been reported in the molting fluid of
Manduca sexta, and it has been suggested that this enzyme is responsible
for the digestion of chitin associated proteins during molting.
addition, a metal chelator-sensitive protease has been identified in
the molting fluid of Manduca sexta, but the nature of the metal ion has
not been established (5). This metalloprotease may be involved in the
digestion of cuticle associated proteins as well as the degradation of
the cuticular chitinase activity (6).
Dur ing the pupal stage, larval tissues are histolysed by both
lysosomal and non-lysosomal proteases (7). The insect hormone ecdysone
stimulates histolysis of the larval muscles by stimulating the pro-
liferation of the lysosomes (8). The involvement of lysosomal pro-
teases is further supported by the finding that homogenates of
Antheraea i larval muscles undergoing histolysis contain a par-
ticulate fraction associated protease with pH optimum of about 4. 0 (9).
Ultrastructural and cytochemical studies on metamorphosing Lepidopterous
larval muscles have shown that the mitochondria and the endoplasmic
reticulum are degraded by the lysosomes (7).
More recent studies have suggested that non-lysosomal proteases
may be necessary to initiate myofibr illar degradation in muscles under-
going histolysis. The main support for this contention der ives from
the finding that neither pepstatin (an inhibitor of the lysosomal pro-
tease cathepsin D) nor chloroquin (an inhibitor of intralysosomal pro-
teolysis) inhibited the dissolution of the organized myofibrillar
structure (10, 11). The origin of non-lysosomal protease (s) is (are)
- -
uncertain, although, it is possible that the phagocytic hemocytes
present in insect muscle undergoing histolysis may be the source.
The mechanisms by which the activities of the molting fluid pro-
teases and the proteases involved in histolysis are regulated is poorly
understood. Histolysis is known to be regulated by neural as well as
hormonal factor s For example, an increase in the ecdysone level and
the cessation of motor impulse to the muscles trigger muscle histolysis
(7) . However, the mechanisms that couple the hormonal and the neural
stimuli to the action of proteases are not known. It is likely that at
least part of the immediate regulation of protease activity involves
protease inhibitors. To the author s knowledge no direct studies on
the control of histolysis by endogenous insect protease inhibitors have
been performed. The lack of information is probably attr ibutable to
two factor s first, histolysis is a complex phenomenon and the pro-
teases involved have not been well character ized; second, protease
inhibitors have been isolated and characterized for only a few insects,
and often no information is available on the histolytic process of the
insect from which the inhibitor was isolated.
B. 2. The Proteolytic activation of insect prophenoloxidase
Phenoloxidases are copper containing monooxygenases, widely dis-
tributed among the eukaryotes, which are capable of oxygenating mono-
phenols to diphenols and further oxidizing diphenols to quinones
(Fig. 1) . In insects, phenoloxidases appear to have important roles
in sclerotization, wound healing, and in insect immunity. In scleroti-
zation, the phenoloxidases generate catechols and quinone derivatives
which crosslink insect cuticular proteins and harden (sclerotize) the
,
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cuticle. Crosslinking of the cuticular proteins locally at the site of
an injury aids wound healing. The quinones generated by the phenolox-
idases have both bacteriocidal and fungistatic properties. In addition,
the quinones form melanin pigments which when deposited on the surfaces
of invading parasites isolate them from the insect tissues. These
melanin depositions attract phagocytic hemocytes and thus promote
insect immuni ty .
There are two classes of phenoloxidases in insects, the cuticular
phenoloxidases and the hemolymph phenoloxidase (s) . The cuticular
phenoloxidases appear to be responsible for sclerotization reactions
while the hemolymph enzyme is thought to playa vital role in insect
defense mechanisms. The cuticular phenoloxidases in turn can be
subqlassified into two types. The first type is sensitive to inhibi-
tion by phenylthiourea and accepts both mono and ortho diphenol sub-
strates. The second type accepts both ortho and para diphenol sub-
strates and are less sensitive to inhibition by phenylthiourea. The
phenylthiourea sensitive phenoloxidases are usually readily solubilized
in aqueous buffers, in contrast to the phenylthiourea resistant type of
phenoloxidases which are difficult to solubilize and often require
limited proteolysis to dissociate them from the cuticle. The properties
of the cuticular phenoloxidases and the chemistry of sclerotization
have been reviewed (12, 13). The hemolymph phenoloxidase is soluble
and is present in both the hemolymph and the herncytes. Hemolymph
phenoloxidase initially was thought to be enclosed within membrane-
bound granules and released when needed (14). However, it is now
generally accepted that the hemolymph phenoloxidase is synthesized as
an inactive proenzyme which is activated by limited proteolysis (15).
Prophenoloxidase has been purified from the hemolymph of the
silkworm Bomb mori (16), from the larvae of the blowfly Calli hora
(17) and from the hemolymph of the tobacco hornworm Manduca sexta (18).
A diisopropylphosphofluoridate-sensitive protease capable of activating
prophenoloxidase has been purified to homogeneity from the cuticle of
Bomb mori (19) and partially purified from Manduca sexta cuticle (18).
In vitro studies using purified preparations of Bomb mori hemolymph
prophenoloxidase and prophenoloxidase activating enzyme from cuticle
have demonstrated that activation involves the cleavage of an activation
peptide of molecular weight . 5000 daltons from a 40, 000 dalton
prophenoloxidase of Bomb mori (20). The prophenoloxidase activating
ser ine protease from Bomb mor i hydrolyzes benzoyl-L-arginine ethyl
ester and tosyl-L-arginine methyl ester, and therefore possesses
trypsin-like specificity. It is still not entirely clear how a pro-
tease present in the cuticle can activate prophenoloxidase present in
the hemolymph (or hemocytes), although several modes may be proposed.
The cuticular activator could be secreted directly into the hemolymph
where it would activate the prophenoloxidase. The cuticular protease
also could activate a hemolymph enzyme which in turn would cleave the
prophenoloxidase. Alternatively the cuticular protease could act on
the prophenoloxidase locally near the site of a wound. The la t ter
mechanism could regulate the extent of prophenoloxidase activity by
preventing disseminated prophenoloxidase activation in the hemolymph.
Sever al microbial polysacchar ides including yeast zymosan,
bacterial endotoxins and laminar in (a fungal polysaccharide) have been
shown to cause activation of prophenoloxidase in the hemolymph of
Bomb rnri (21) and in the hemocytes of Galleria mellonella (22).
Purified Bomb mori prophenoxidase is not activated by laminar 
confirming that an additional factor is necessary to couple the micro-
bial polysaccharide stimulation to the activation of the prophenolox-
idase . The exact sequence of reactions which couple microbial poly-
saccharide stimulation to prophenoloxidase activation in insects is not
clear, although similar studies on the activation of prophenoloxidase
in hemocyte lysates of the crayfish Astacus astacus demonstrated that
at least one serine protease is involved (23).
Once formed, the enzyme phenoloxidase catalyses the formation of
melanin pigments, and the melanization reaction has been demonstrated
to induce host defense responses such as phagocytosis (24). The
addition of p-nitrophenyl p' guanidinobenzoate (an inhibitor of trypsin-
like proteases) to Galleria mellonella hemocyte culture completely
blocks both prophenoloxidase activation and phagocytosis, suggesting
that phagocytosis and prophenoloxidase activation both require a
trypsin-like protease activity (22). Histological studies have defined
the relationship between melanin formation and phagocytosis: prophe-
noloxidase present in the granulocytes (a typ of hemocyte) is secreted
onto a foreign surface (e.g. bacterial cells) when the granulocytes
come in contact with them and is subsequently activated. The activated
phenoloxidase catalyses the formation of melanin pigments, and these in
turn stimulate phagocytosis by phagocytic hemocytes (22). The poss ible
. I'
sequence of events which culminates in the phagocytosis of foreign
mater ial in the hemolymph is presented in Fig. 
The activation of the prophenoloxidase system in insects (and in
arthropods in general) is analogous to the initial events in the acti-
vation of the alternative pathway of complement (21, 25) in mammals.
Microbial polysaccharides are known to stimulate both systems, and in
the process proteolytic enzymes are activated. However, it is not
known if insects have a complement-like system.
Although the importance of phenoloxidase in insect physiology is
well recognized, very little is known concerning the control of the
proteases involved in the acti va tion of prophenoloxidase. In par-
ticular the role of hemolymph protease inhibitors in the regulation of
prophenoloxidase activation has not been examined in insects. One of
the aims of this research was to determine whether the hemolymph
trypsin inhibitors of Manduca sexta had any role in the regulation of
prophenoloxidase activation in this insect.
The activation of the insect coagulation system
The hemolymph of insects serves a similar function as the verte-
brate blood, although, it differs from it in not having erythrocytes.
Cells present in the hemolymph are termed hemocytes and are compr ised
of a complex group of cells der i ved from the mesoderm. All hemocytes
are nucleated cells which resemble vertebrate leukocytes. A clear
classification of insect hemocytes is difficult because of their
pleiomorphism. The seven major hemocyte types described by Arnold (26)
and Crossley (27) are listed in Table 1 along with their putative
function (s) .
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Table 
List of hemocyte types in insect hemolymph
Hemocyte type
a) Prohemocyte
b) Plasmatocytes
c) Granulocytes
d) Adipohemocytes
e) Cystocytes(Thrombocytoids)
f) Spherulocytes
g) Oenocytoids
Suggested function(s)
Ellipsoidal cells which are the
germinal stem cells that differ-
entiate into other cells.
Pleiomorphic cells , has lysosomal
apparatus , mainly phagocytic* in
function.
Disk shaped cells with many per-
iodic-Schiff pos it i ve granules.
Involved in phenol metabolism*
has phenoloxidase activity.
Prominent fat globules; lipid and
other intermediary metabolism.
Fragile cells that lyse and cause
granular precipate in the surrou-
nding plasma. Also called coagulo-
cytes , funct ions in hemolymph *
coagulation.
Function similar to granulocytes.
Unstable cells which discharge
their contents rapidly. Cytoplasmhas crystal-like inclusions.
Function not clear , may have function
similar to granulocytes.
* Indicated function is carried out by more than one cell
type.
Many soft bodied invertebrates such as the molluscs prevent hemor-
rhaging by simply closing the wound by muscular contraction. By con-
trast, most arthropods, both in the larval and the adult stage possess
a rigid exoskeleton and hence cannot close the wound by simple muscular
contraction. Arthropods, therefore, must possess an effective hemo-
static mechanism which will prevent the loss of a large quantity of
hemolymph after being wounded. The clotting of the hemolymph observed
in many arthropod species, including Xiphisura (e.g., horse shoe crab)
(28), Crustacea (e.g., crabs and shrimps) (29) and Insecta (e.g., 10-
custs, roaches) (30, 31), serves as an effective hemostatic mechanism.
The biochemistry of coagulation in insects has not received as
much attention as ,the biochemistry of the mammalian coagulation system.
The clottable protein, coagulogen, has been pur ified from the hemolymph
of the roach Leuco haea maderae (32), and has been shown to be a lipo-
protein. Coagulogen of locusts has also been shown to be a lipoprotein
(33) . The clotting of roach hemolymph is strongly inhibited by EDTA,
+2 
and both a an can reverse this inhibition suggesting that
divalent cations are needed for the clotting process (31). In addition
to divalent metal ions, a hemocyte derived factor appears to be es-
sential for coagulation (34). The nature of this factor in insects is
not clear, but in crustaceans this factor has been shown to be a pro-
tease (29). Although the details of the activation reactions has not
been described for insects, a cascade of proteolytic activities is
likely to be involved in the activations since (a) larval bee hemolymph
was shown to contain activities functionally equivalent to all the
human coagulation factors, except Factor VII activity (35), and (b) the
hemolymph coagulation of another ar thropod, the hor se shoe crab, has
been shown to be activated by a cascade of proteases (31). Mammalian
blood protease inhibitors have been shown to be important in the control
of the blood coagulation process, and it is likely that protease
inhibitors in insect hemolymph also play an important role in the control
of the clotting process.
Protease Inhibitors - An Overview
Proteolytic enzymes serve as key agents of biological regulation
in all living organisms (36, 37). Hence, it is not surprising that
protease inhibitors have been isolated from such diverse organisms as
bacteria (38) and man (39). The protease inhibitors of mammalian and
plant or igin have been studied extensively, and their biochemistry has
been summarized in several reviews (40, 41, 42).
The amino acid sequences of many protease inhibitors have been
elucidated. Based on their pr imary structures, Laskowski and Kato have
proposed a system to classify the serine protease inhibitors into eight
major families (41). Although this system fails to include the protease
inhibitors whose primary structures are not known, it has been useful
for comparing properties of inhibitors of diverse origin. The most
extensively studied families are the bovine pancreatic trypsin inhibitor
(BPTI, Kuni tz) family, the pancreatic secretory trypsin inhibi tor (PSTI,
Kazal) family and the Bowran-Birk family of inhibitors. The BPTI
(Kunitz) family of inhibitors have a wide distribution and are found in
both vertebrates and invertebrates. The PSTI (Kazal) type of inhibitors
have been shown to be present in large amounts in pancreatic secretions
of mammals, and the Bowran-Birk family of inhibitors are widely dis-
tributed among the plant kingdom.
In contrast to the mammalian and plant protease inhibitors, much
less is known about the biochemistry and the regulatory functions of
insect protease inhibi tor s . Both trypsin and chymotrypsin inhibitors
have been descr ibed in the larval homogena tes of Droso h ila (43), and
in the alimentary tract of the tse-tse fly, Glossina morsitans (44),
and the roach, Leuco haea maderae (45). Chymotrypsin specific inhibi-
tors have been isolated from whole body homogenates of Droso hila (46),
and from the mosquitoe Culex iens (47).
Trypsin and chymotrypsin inhibitory activities have been reported
in the hemolymph of the silkworms, Antherarea ern i and philosamia
thia ricini, but, these have not been purified (48). The hemolymph
of the commercial silk worm Bomb mori contains high molecular weight
( ;) 40, 000 dalj:ons) and low molecular weight (c: 20, 000 daltons)
inhibitors which inhibit trypsin and/or chymotrypsin (49, 50).
date, 7000 dalton and 43, 000 dalton chymotrypsin-specific inhibitors
and a 42, 000 dalton trypsin inhibitor have been isolated from the
hemolymph of Bomb mor i A list of insect protease inhibitors which
have been purified to homogeneity is given in Table 
The significance of protease inhibitors in
biological processes
Viewed in the broadest sense, the physiological function of
protease inhibitors would be to eliminate unwanted proteolysis. with
few exceptions, the function of specific protease inhibitors have not
been determined. The underlying reason for this lack of clarity of
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function is that for the most part protease inhibitors were purified
and characterized using readily available proteases such as bovine
trypsin or chymotrypsin, and consequently, the physiological target
enzymes of these inhibitors are unknown. A trypsin inhibitor whose
function has been well established is pancreatic secretory trypsin
inhibi tor (PSTI, Kazal). This inhibitor prevents the premature
activation of trypsinogen prior to secretion, and thus protects the
pancreas from the deleterious effects of trypsin (41). Likewise, the
human serum proteinase inhibitor has been shown to protect the
lungs against leukocyte elastase (39).
-Interestingly, some plants use protease inhibitors as an effective
defense against insect infestation. In response to injury by insects,
potato leaves accumulate large amounts of chymotrypsin and car-
boxypeptidase inhibitors (51) which presumably inhibit the insect di-
gestive proteases and prevent insects from feeding.
Three possible biological roles have been proposed for the pro-
tease inh ibi tor s in insect hemolymph. First, these inhibitors may in-
hibit proteases that leak into the hemolymph from other tissues,
especially the alimentary tract. Secondly, they may serve to regulate
the activities of proteases normally present in the hemolymph, such as
the proteases involved in activation of prophenoloxidase and the coagu-
lation systems. The presence of large amounts of protease inhibitors
in the hemolymph of Bomb mori , Antherarea ern i, and Philosamia cyn-
thia ricini suggests an important role for these protease inhibitors in
the control of proteolytic activation. Thirdly, the hemolymph protease
inhibi tors could protect against the proteases of invading parasites.
For example, the hemolymph of the silkworm, Born mor i has been shown
to inhibit proteases derived from the fungus, As illus mellus (48).
A moel for the interaction of serine protease with serine
protease inhibitors: the case of bovine
pancreatic trypsin inhibitor and bovine trypsin
pOlypeptide protease inhibitors form tight complexes with their
respecti ve proteases. The general mechanism for the interaction of
serine proteases with their inhibitors may be depicted as follows:
E + I (comPlex) E + I*
Where E represents the ser ine protease, I is the virgin inhibitor
and I* is the modified inhibitor (inhibitor whose reactive site peptide
The (comPlexJ represents a collectionbond is hydrolysed - see below).
of several intermediate steps which leads to the formation of a rela-
t i vely stable protease- inhibi tor species. Protease inhibitors display
the characteristics of excellent substrates for the association step
(kl ), but in contrast to hydrolysable substrates, are inhibitors by
virtue of their slow dissociation (k2 + k l) constants (52).
All polypeptide inhibitors of serine proteases contain at least
one amino acid which is specifically recognized by its complementary
protease, and a few inhibitors possess amino acid residues which are
recognized by several proteases possessing different specificities.
These latter inhibitors are know as multiheaded inhibitors (53). The
amino acid which denotes the specificity of the inhibitor is termed the
PI residue (Fig. 3) (40). For endopeptidase inhibitors the amino acid
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residue on the carboxy-terminal side of PI is designated as the PI
residue. The peptide bond linking the PI and the PI ' residues is
designated the reactive site peptide bond (Fig. 3). For example, in
BPTI the peptide bond between Lys 15 and Ala 16 has been shown to be
the reactive site peptide bond (Fig. 3).
The physico-chemical and kinetic aspects of the interactions of
bovine pancreatic trypsin inhibitor (Kunitz) (BPTI) and soybean trypsin
inhibitor (Kunitz) (SBTI) with bovine trypsin have been studied 
depth (52, 55, 56, 57). Moreover, the crystalline structures of the
BPTI-bovine trypsin and the SBTI-porcine trypsin complexes have been
elucidated, and we now have a clear understanding of the mechanism of
action of these serine protease inhibitors (58, 59). The Manduca sexta
hemolymph trypsin inhibitors reported here have strong sequence
homology to BPTI. Therefore, BPTI-bovine trypsin interaction was
chosen as a ,model for studying the interaction of insect hemolymph
inhibitors with trypsin. In order to descr ibe the nature of the
complex formed between BPTI and bovine trypsin a br ief descr iption of
the mechanism of trypsin catalysis is presented below.
The three amino acid residues intimately involved in the catalytic
mechanism of trypsin are Ser 195* , His 57 and Asp 102. The sequence of
events in trypsin catalysis is presented in Fig. 4. Polypeptide sub-
strates bind to trypsin such that the trypsin labile peptide bond of
the substrate is precisely oriented for nucleophilic attack by Ser 195
of tryps in. The favored mechanism for serine protease catalysis
*Note: The chymotrypsinogen enumeration has been followed throughout
for describing the primary structure of trypsin and chymotrypsin.
Substl'te
Ser 195
-CH O=C
R-N-H
Tetrahedral
trnsition state
Acyl.enzyme
intermediate
N-CH
His 57 : CH
Asp 102 
Acl-enzyme
intermediate
-CH -0""C' H
1H 
: ?HHis 57
Asp 102
-CH -0
/ ""
R-N-H
N-CHH( 
N-C
7 ?H
" /
_CH _0""C..
R-N-H
, N-CH
N-C
: CH
Tetrahedral
tl'nsition state Acid componentof the substrate
-CH
H(lH 
N-C
H ?H
" /
o=c
O-H
N-CH
N-C
: CH
0- I
-CH
Fig. 4. The sequence for trypsin-catalyzed
hydrolysis of a peptide bond.
involves transfer of a proton from Ser 195 to His 57 and the formation
of a covalent bond between the carbonyl carbon of the substrate peptide
and Ser 195. This is the tetrahedral intermediate (#2 in Fig. 4). The
tetrahedral form collapses to form the acyl enzyme intermediate (#3)
wi th the subsequent release of product 1. Deacylation occurs by the
reverse mechanism whereby water attacks the carbonyl carbon of the acyl
enzyme intermediate to form a second tetrahedral intermediate (#5)
which then collapses to regenerate the enzyme and the second product,
the free acid.
Studies on the BPTI-trypsin complex have demonstrated that poly-
peptide inhibitors bind to the catalytic and not to an allosteric site
on their target protease. Evidence to support this is derived from
several studies (a) selective modification of the active-site Ser 195
of trypsin by DFP or the active site His 57 by tosyl-L-lysyl chloro-
methylketone abrogate binding of the inhibitor (60), (b) the
association rate constant of BPTI-trypsin interaction is dependent on
the ionization of a group with pKa of 7. 05, presumably His 57, (55),
and (c) x-ray crystallographic studies of the BPTI-trypsin complex con-
firm the binding of the polypeptide inhibitor to the active site of
trypsin (58).
The major structural determinants of the pear-shaped BPTI
molecule are two
-sheet regions, extending from Ala 16 to Gly 36,
which are linked by a disulfide bond at the top of the molecule (see
Fig. 5). The complex of BPTI wi th trypsin is mushroom-shaped with
trypsin forming the "head" and BPTI forming the " stalk" In the
Fig. 5. Diagram illustrating the polypeptide back-
bone of BPTI.
representation of Fig. 5, the trypsin "head" is positioned on top of
the depicted BPTI " stalk" , cover ing, among other amino acids, the
disulfide bond between cysteines 14 and 38. The complex formation is
accompanied by very little structural change in the three dimensional
structure of either trypsin or the inhibitor. The BPTI-trypsin complex
is tightly packed (57), and exclusion of water molecules at the contact
surfaces of trypsin and the inhibitor greatly enhances the stability of
the complex.
Two segments of the BPTI polypeptide chain are intimately associ-
ated with trypsin (61). The first segment extends from Gly 12 to Ile
18 and the second segment extends from Tyr 35 to Arg 39. Table 3
depicts the most important amino acids in contact between trypsin and
BPTI, and the type of bonding between the interacting amino acids.
There are 10 hydrogen bonds formed between BPTI and trypsin.
addition, more than 200 van der Waals interactions are established.
The interactions of the major contact residues between BPTI and
trypsin are illustrated in Fig. The contact residues of the BPTI
molecule fit precisely within the catalytic site of trypsin. The
specificity pocket of trypsin, which is formed by residues 189-194 and
214-219 accommdates Lys 15 of BPTI. The e: -amino group of Lys 15 of
BPTI hydrogen bonds with the S-carboxyl group of Asp 189 of trypsin.
The polypeptide sequence Pro 13-Cys 14-Lys 15 of BPTI forms a short S-
sheet-like structure with the segment Ser 214-Trp 2l5-Gly 216 of
trypsin. The residues Ala 16-Arg 17-Ile 18 of BPTI are close to Tyr
39-His 40-Phe 41 of trypsin. The a-amino group of Arg 17 forms a
hydrogen bond with the carbonyl oxygen of Phe 41, and the guanidinium
TYR 39
HIS 40
PHE 41
CYS 42
HIS 57
CYS 58
TVR 59
LYS 60
SER 96
ASN 97
THR 98
;: LEU 99
;. TYR 151
GL 175
ASP 189
SER 190
CYS 191
GL." 192
GLY 193
ASP 194
SER 195
SER 
TRP 215
GLY 216
Table 3,
List of some of the residues involved in
trypsin-BPTI interaction
BPTI
GLY PRO CYS LYS ALA ARG ILE VAL TYR GLY GLY CYS ARG
. V
, V
, V
H.Hydrogen bond; S-Salt bridge; V-van der Waals contacts
1-/
s.,
/C'
'8cu
. , .. ! 
Fig. Schematic drawing illustrating the major
contact residues between BPTI and the
active site region of bovine trypsin.
(BPT! amino acid residues are colored red) 
group of Arg 17 forms a hydrogen bond with the carbonyl oxygen of His
40. The polypeptide segment of BPTI from Gly 36 to Cys 38 lies close
to His 57 of trypsin and establishes several van der Waals contacts
with the latter residue. This portion (i. e. Gly 36 to Cys 38) of the
inhibitor restricts the flexibility of the imidazole ring of His 57 of
trypsin which must occur dur ing the course of trypsin catalysis.
In the BPTI-trypsin complex, the peptide bond of BPTI between Lys
15 and Ala 16, which corresponds to the scissile peptide bond of a
protein substrate, is oriented such that the I-oxygen of Ser 195 of
trypsin lies almost perpendicular above the plane of the Lys 15 carbonyl
car bon. This arrangement favors a nucleophilic attack by Ser 195 along
the tetrahedral bonding direction of the Lys 15 carbonyl carbon.
However, in contrast to substrate catalysis (cf. trypsin catalytic
mechanism on page 20), a tetrahedral intermediate does not form.
Instead, the Lys 15 carbonyl carbon is distorted midway between trigonal
and tetrahedral conformations. The stable complex formed between BPTI
and trypsin represents an intermediate stage of catalysis and is
frozen " by the constraints imposed by the enzyme and the inhibitor.
The focus of the present study was the purification and character 
zation of two relatively heat stable trypsin inhibitors, trypsin in-
hibitors A and B, which occur in the hemolymph of the tobacco hornworm
Manduca sexta. Both trypsin inhibitors A and B have striking amino
acid sequence homology to BPTI and also exhibit similar physicochemical
character stics . Hence, it was reasonable to expect that the inter-
action of these inhibitors with trypsin would be similar to that of the
well-character ized BPTI-bovine trypsin complex. Therefore, the
structure and properties of trypsin inhibitors A and B of Manduca sexta
were compared with BPTI in order to identify and define the possible
structure-function parameters of the Manduca sexta inhibitors.
CHATER I I
EXPERIMENTAL PROCEDURS
Mater ials
Tritiated iodoacetic acid (specific activity 50-100 mCi/mrole) was
obtained from Amersham (Arlington Heights, IL) and diluted with re-
crystallized sodium iodoacetate to 2 mCi/mmole. Aldr ich Chemical Com-
pany (Milwaukee, WI) supplied tr iethylamine, L-Dopa and glutaralde-
hyde . Electrophoretic grade acrylamide, N, N I -methylenebis acrylamide,
sodium dodecyl sulfate, Biolyte (ampholyte 3-10) and coornassie blue
dye reagent concentrate for protein estimation, by the method of Bradford
were products of Bio-Rad Laboratories (Richmond, CA). Dithio-threi tal,
p-ni trophenyl p ' guanidinobenzoate, Azocoll, and thermolysin were from
Calbiochem (La Jolla, CA). Electran (brand name of low molecular weight
standards) was obtained from Gallard-Schlesinger (New York, NY). Milli-
pore Corporation supplied the 0. m MF type filters. Subtilisin BPN 
was purchased from Nagase Chemical Company, Osaka, Japan. Sephadex G-
75 (superfine), Sepharose 4B, Sephadex G-IOO (superfine) and blue
dextran were obtained from Pharmacia Chemical Company (Piscataway, NJ).
The silver stain kit used for protein staining polyacrylamide gels was
manufactured by Polysciences (Warrington, PA). Sigma Chemical Company
(St. Louis, MO) supplied the following: N-benzoyl
-DL-arginine p-nitro-
anilide (BAPNA) , glutaryl- phenylalanyl-p-nitroanilide (GPNA), 4-
methylumbelliferyl p-tr imethylarnnium cinnamate (MUMAC), sodium
iOdoacetate, guanidine hydrochloride, laminar in, tris, trypsin, ribonu-
clease A, chymotrypsinogen, pepsin, horse heart myoglobin, Aprotinin,
papain, hemoglobin, plasmin, case in, thrombin, and f ibr inogen . Dialysis
tubing (Spectraphor M.W. cut off 3, 500) was supplied by A. Thomas
and Company (Philadelphia, PA). Chymotrypsin, L-l-tosylamido-
phenylethyl chloromethyl ketone-treated trypsin (trypsin-TPCK), and
porcine elastase were products of Worthington (Freehold, NJ). All other
chemicals were of reagent grade.
Methods
Assays and techniques
(a) Assa for tr sin inhibitor activit
Inhibitory activity toward trypsin was measured and quantified
using BAPNA as the trypsin substrate. The assay mixture consisted of
1 M tris-HCl buffer pH 8. 3, 1 rn BAPNA, 2 g of bovine trypsin, 20 rn
CaC12 and the inhibitor in a total reaction volume of 1. 0 mI. Typically
the mixture was incubated at 35 C for 30 minutes, the reaction termi-
nated by the addition of 0. 5 ml of 30% v/v acetic acid, and the liberated
p-nitroaniline was measured at 410 nm. Under the conditions of the
assay the amount of p-nitroaniline liberated was linear for at least 45
minutes. The percentage inhibition (%I) was calculated using the formula
%I = (1 - ) x 100
where AI and Ao represent the absorbance in the presence and the ab-
sence of the inhibitor respectively. The concentration of the inhibitor
measured in these assays was chosen to give values that were between
o . 5 and o. 7 Ao. Under the given conditions one unit of inhibitor
activity was defined as the amount of inhibitor that caused a 50%
inhibition of the hydrolysis of BAPNA by 2 . 50 pmoles) of trypsin.
(b) Protein determination
During purification of the trypsin inhibitors A and B, protein was
estimated by the coommassie blue dye binding method of Bradford (62)
using bovine serum albumin as the standard. However, this method could
not be employed with the purified inhibitors because they were found to
bind the dye weakly. Therefore, quantitation of the purified inhibitors
was performed on a amino acid analyzer.
(c) SDS- acr lamide el electro horesis
Sodium dodecyl sulfate slab gel electrophoresis was performed
according to the method of Laemmli (63) except that the resolving gel
consisted of a gradient between 10-20% acrylamide and the stacking gel
was 1% acrylamide.
Samples were prepared for electrophoresis by boiling in 0. 15 M
tris-HCl buffer pH 6. 8, containing 5. 7% SDS, 30% glycerol, and 14% 8-
mercaptoethanol. Bromophenol blue (0. 005%) was added as the tracking
dye. The gels were electrophoresed at SO V for 15 hours using cold tap
water to cool the electrophoresis unit. Cyanogen bromide cleaved frag-
ments of horse heart myoglobin (Electran brand M. W. standards) were
used as molecular weight mar kers. The gels were stained in the follow-
ing manner: Gels were fixed in 50% methanol, 12% acetic acid for 90
minutes, followed by 3 x 20 minute washes in a mixture of 10% ethanol
and 5% acetic acid and 2 x 10 minute washes with deionized water.
order to enhance the silver reaction with the inhibitors, the gels were
pretreated with 10% glutaraldehyde for 90 minutes followed by 6-
rinses with deionized water and then stained in 1% ammoniacal silver
nitrate solution for 20 minutes. The gels were washed with deionized
water until the washings were negative for silver ions and the protein
bands were developed by immersing the gel in a 0. 02% citric acid solu-
tion containing 0. 18% formaldehyde.
(d) Determination of isoelectric oint b isoelectrofocusin
The isoelectr ic point of each inhibitor was determined using 10%
polyacrylamide gels (10 cm x 8 cm x 1. 5 mm) in the presence of pH 3-
polyelectrolytes. Approximately 15 of each inhibitor was electro-
focused at 200 V and 7 C overnight, the gels were sliced into 6 mm
hor izontal sections and the pH of each slice was measured using a sur-
face elctrode. Each slice was extracted with 20 rn tr is-HCl buffer
containing 50 rn NaCl pH 7. 5 and the inhibitory activity towards
trypsin was measured.
(e) Assessment of com lement Factor B cleava e b
immunoelectro hor es is
One percent agarose slabs were cast on clean dry 35 mm x 75 mm
microscope slides. Two sample wells were punched on each agarose slab
and each well was filled with one of the experimental mixtures (obtained
by incubating complement factor B or fresh frozen human serum with
different reagents as descr ibed on page 51) and electrophoresed at 7.
mA per slab for about 5 hours in 0. 1 M veronal buffer, pH 8. 6 containing
5 rn EDTA. Following electrophoresis, a central trough was excised
between the two wells and filled with 200 l of rabbit antifactor B
antiserum. Precipitin bands were allowed to develop overnight at room
temperature in a humidity chamber.
(f) Amino acid anal sis of tr sin inhibitors A and B
Samples of trypsin inhibitors A and B were dialysed against water,
separately dispensed into clean pyrex tubes and lyophilized. Two hun-
dred microliters of 5. 75 N HCl was added, and the samples were hydro-
lyzed vacuo at 110 C for 24 hours. The hydrolysates were dried 
vacuo over phosphorous pentoxide and they were analyzed for amino acid
content by the method of Jones et ale (64). Cysteine was quantitated
as cysteic acid after performic acid oxidation (65).
(g)
Reduction and S-carbox eth lation of tr sin inhibitors A and B
One milligram samples of inhibitor A or B were dissolved in 1 ml
5 M tris 7. 5 M, guanidinium chloride, pH 8. 0, containing 0. 01 M DTT,
and allowed to reduce under nitrogen for 1 hour at room temper ture.
Two hundred and fifty microliters of 2- 
PH) 
iodoacetic acid solution
(250 Ci, specific activity 2. 0 mCi/mmle) was added, the samples were
flushed with nitrogen and S-carboxyrethylation performed at room
The H) -S-carboxymethylated inhibitors
were dialysed against water using 3, 500 M. W. dialysis tubing until less
temperature for 30 minutes.
than 50 cpm of radioactivity were detected per ml of water and then
were lyophilized.
For peptide mapping exper iments, samples were reduced and S-
carboxymethylated using the same protocol except that nonradioactive
iodoacetic acid was used.
(h) tide ma of tr sin inhibitors A and B
Approximately 450 g of each reduced and S-carboxymethylated
trypsin inhibitor was dissolved in 100 l of 0. 1 M ammnium
bicarbonate, pH 7. 8, and digested for 18 hours with 1. 5% (w/w) trypsin-
TPCK at 37 At the end of the digestion, 10 l of glacial acetic
acid was added to arrest the reaction, and the samples were
lyophilized. The peptide mixture was redissolved in 100 1 of 0.
trifluoroacetic acid and injected onto a 4. 6 rn x 75 rn Altex-Ultrapore
RPSC C3 column equilibrated with 0. 1% trifluoroacetic acid. Peptides
were separated using a gradient between 0-75% acetonitrile in 0.
trifluoroacetic acid and the peptide fractions were collected manually
by monitoring the absorbancy at 206 nm.
( i) Determination of the aminoterminal amino acid se uences of tr sin
inhibitors A and B
Amino terminal amino acid sequences were obtained on 10-16 nmole
of reduced and PH)-s-carbOXymethYlated inhibitors using a moified
Beckman 890C sequenator adapted for microsequencing (66). The phenyl-
thiohydantoin der ivatives of amino acids (PTH amino acids) were identi-
fied and quantitated using two independent reverse phase systems. The
pr imary system utilized a 6 m Zorbax C18 HPLC column and a 12 minute
25-52% acetonitrile gradient in sodium acetate buffer pH 4. These
identifications were confirmed using a 5 Ultrasphere C18 column and
a linear methanol gradient (20-45%) was employed. All data were
quantitated with a Hewlett Packard 3390A integrator using PTH
nor leucine as an internal standard. S-carboxymethyl cysteines were
confirmed by counting an appropr iate aliquot of each cycle for
radioactivi ty.
(j)
Secondar structure redictions for tr sin inhibitors A
and B usin Chou and Fasman calculations
For the calculation of secondary structure, the rules of Chou and
Fasman were followed (67). In this method, numer ical "conformational
parameters " are computed to give the probability of a particular amino
acid residue being found in helix (Pa ) or S-pleated sheet structure
(PS ). Depending on the numer ical value of Pa and Ps the amino acids
are classified into "strong formers" (either a-helix or S -plea ted
sheet), " formers , "indifferent"
, "
breakers" and "strong breakers"
When four helix formers out of six residues are clustered, there is a
greater probability of an a-helix structure. Propagation can then
occcur in both directions until it is terminated by a tetrapeptide of
helix breakers. Likewise, if three out of five s-pleated sheet formers
are clustered, nucleation of a S-pleated sheet may occur. As in the
case of a-helical structure, the propagation of S -pleated sheet may
occur in both directions until it is terminated by a tetra peptide
sequence of S-pleated sheet breakers.
(k) Pre aration and titration of rea ents for com lement factor Band
factor D assa
Sixty milliliters of human venous bloo was drawn and allowed to
coagulate in Corex centrifuge tubes. After allowing the clot to
retract at 4 C for two hours the blood was centr ifuged and 5 ml
portion of the clear serum was divided into 0. 5 ml aliquots and frozen
immediately at -
In order to titrate the alternative pathway components in fresh
frozen serum, 10 l of freshly washed rabbit erythrocytes (3. 5 x 109
cells/ml) in GVBS was incubated at 37 C for 1 hour with 25 1 of fresh
frozen serum ser ially diluted two fold with GVBS in a total reaction
volume of 150 Ten microliters of rabbit erythrocyte (3. 5 x 109
cells/ml) diluted into 140 l of deionized water served as the total
hemolysis control. One milliliter of ice-cold GVBE was added to each
incubation mixture to terminate the reaction, the cells were centr ifuged
at 1, 200 x g and the absorbance of the supernatant was measured at 414
nm.
Factor B depleted serum (RB serum) was prepared by inactivation of
fresh serum (23 ml) at 52 C for 30 minutes. Twenty five microliters
of RB serum was reconstituted with 4 g of purified factor Band titered
as descr ibed for fresh frozen serum. RB serum was then divided into
5 ml aliquots and frozen at -70
Factor D depleted serum (RD serum) was prepared by depleting factor
D on a Bio-Rex 70 ion exchange resin (68). Titration of RD serum was
performed in an analogous manner to the titration of RB serum except
that functionally pure factor D (Bio-Rex 70 eluate) was used to recon-
stitute the RD serum. For assays of factor s Band D in Manduca sexta
hemolymph, a 1: 3 dilution of RB and undiluted RD sera were used.
2. Measurement of trypsin inhibitor activity in the hemolymph of
Manduca sexta dur ing larval-pupal metamorphosis
A batch of synchronously developing larvae were divided into three
groups of 10 animals each and bled individually into polypropylene tubes
at the fifth instar of larval development (27 days), dur ing the ear 
pupal stage (31 days) and during the late pupal stage (38 days) . Five
to twenty microliters of the crude hemolymph was used to measure trypsin
"- _
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inhibitory activity, which was expressed as units of inhibitor
acti vi ty /ml hemolymph.
Isolation and characterization of trypsin inhibitors from
the hemolymph of Manduca sexta
(a) Collection of Manduca sexta hemolymph
The tobacco hornworm, Manduca sexta, was grown in our laboratory
on a wheat-germ-agar diet as described by Yamamoto (69). The eggs were
obtained from the Metabolism and Radiation Research Laboratory (Fargo,
ND) or the Tobacco Research Institute (Oxford, NC). The growth
temperature was maintained at 26 + 1 C and the larvae were kept on a
photo per iod of 12 hours. Under these conditions the larvae grew to
their maximum size (10- 12 g) in bout 25 days. Hemolymph was collected
from the larvae dur ing the fifth ins tar before they entered the
wandering stage (before their dorsal blood vessel became prominent) 
The hemolymph to be used for inhibitor pur ification was obtained by
cutting one of the hind legs and gently squeezing the hemolymph into an
equal volume of ice-cold bleeding buffer (20 mM tr is-HCl, containing 1
mM phenylthiourea and 0. 02% sodium azide, pH 7. 5). Between 1 and 1. 
ml of hemolymph was obtained from each animal. Hemolymph from
approximately one hundred larvae were pooled, centr ifuged at 4 C for
30 minutes at 15, 000 rpm (SS 34 rotor) in a Sorvall RC-2B centrifuge
and the clear blue-green supernatant was frozen immediately at -
until further use.
For studies on inhibitory properties of purified Manduca sexta
hemolymph trypsin inhibitors on the activation of hemocyte prophenolo-
xidase and on the human alternative complement pathway, the larvae were
bled into an equal volume of 10 rn cacodylate buffer, pH 7. 0 containing
25 M sucrose and 0. 1 M sodium citrate (buffer P) in order to prevent
++ -dependent preactivation of proteases secreted by hemocytes into
the hemolymph. The hemolymph (40 ml) was centrifuged at 1, 000 x g, the
supernatant was divided into 0. 5 ml aliquots and immediately frozen at
The hemocyte pellet (approximately 3 X 108 cells) ' was washed
twice and resuspended in 3. 0 ml of ice-cold buffer P lacking citrate
and used in experiments to evaluate the effect of pur Hied trypsin
inhibitors A and B on the activation of hemocyte prophenoloxidase.
(b) Pre aration of immobilized tr sin
Sepharose 4B was washed with deionized water and sucked "dry" on a
Buchner funnel. Two hundred and twenty-five grams of Sepharose was
resuspended in 225 ml of 60% acetone, chilled to - C and 7 g of
cyanogen bromide dissolved in 10 ml of acetoni tr ile was added. Seventy
milliliters of 1. 5 M triethylamine in 60% acetone was added dropwise in
order to enhance the electrophilicity of the cyanogen bromide, and thus
promote the rapid activation of Sepharose (70). The mixture was stirred
for 10 minutes and poured into an ice-cold mixture of 0. 1 N HCl-acetone
(1:1) . The activated Sepharose was washed with one liter of cold 60%
acetone, one liter of coupling buffer (0. 1 M sodium bicarbonate contain-
ing 0. 5 M NaCl, pH 8. 3), resuspended in 225 ml of coupling buffer and
3 g of trypsin in 50 ml of coupling buffer was added. Coupling was
carried out with agitation at room temperature for 3 hours and the gel
was transferred to 0. 2 M glycine, pH 8. 0 and shaken overnight (blocking
reaction) . Approximately 75% of the trypsin was bound to activated
Sepharose. The substituted gel was washed with 4 liters of ice cold
coupling buffer, 4 liters of cold 0. 1 M sodium acetate buffer containing
5 M NaCl, pH 4. 5, and finally with two liters of 20 mM tris containing
o. 5 M NaCl, pH 7. O. The trypsin-Sepharose gel was stored at 4 C in 20
mM tris-HCl buffer pH 7. 0 with 0. 02% sodium azide as a preservative.
(c) Protocol for the urification of tr sin inhibitors A and B from
the hemolymph of Manduca sexta
During the purification of the hemolymph trypsin inhibitors all
operations were performed at 0-4 C unless otherwise indicated. Crude
hemolymph (315 ml) was thawed in an ice-bath and 35 ml of ice-cold 7%
perchloric acid was added dropwise 
(final pH 5) under stirring to
precipi tate the acid-insoluble proteins. The milky mixture was stirred
for 15 minutes and centr ifuged at 27, 000 x g for 30 minutes. The clear
. gOlden-yellow supernatant was passed through a pad of glass wool to
remove small amounts of floating lipids and the pH readjusted to 6.
0 +
2 with 30% KOH. A slightly acidic pH was found to be essential at
this stage for preventing the oxidation of endogenous hemolymph phenols.
Two hundred and twenty-two grams of solid ammonium sulfate was added
slowly to 335 ml of acid precipitated hemolymph supernatant to bring
the final concentration to 90% saturation.
The solution was stirred on
an ice bath for 1 hour and the precipitated proteins were collected by
centrifugation at 27, 000 x g for 30 minutes.
The precipitate was redissolved in 20 ml of 20 mM tris-HCl buffer
containing 50 mM NaCl, pH 7. 5 (buffer A) and dialyzed against 4 liters
of buffer A overnight. The dialysate was clarified by centrifuging at
27, 000 x g for 30 minutes and loaded onto a 2 x 6. 5 cm trypsin-Sepharose
colum in buffer A at a flow rate of 15-20 ml/hour. The column was
washed successively at a flow rate of 50 mljhour with 100 ml of buffer
A, I liter of 20 rn tris-HCl pH 7. 5 containing 1 M NaCl (buffer B) and
300 ml of 1 rn HCl pH 3. 2 2 (buffer D). Trypsin inhibitor activity
was eluted at a flow rate of 15 ml/hour with 0. 1 M HCl containing 0.
M NaCl (pH 1. 5). The eluted fractions (2 ml) were immediately neutral-
ized by collection into 0. 5 rn of 1 M tris-HCl pH 8. 3 and assayed for
trypsin inhibitory activity. The active fractions were pooled (40 ml)
dialyzed against 4 liters of deionized water and lyophilized.
Sephadex G-7S (superfine) prepared according to the manufacturer
recommendations was packed to a bed height of 95 cm in a 1. 6 cm x 100
cm Pharmacia column and equilibrated with 20 rn tris-HCl buffer pH 7.
containing 0. 5 M NaCl (buffer C). The lyophilisate from trypsin-
Sepharose chromatography was redissolved in 1. 5 ml of buffer C, centri-
fuged to remove the small amount of insoluble material and fractionated
over the G-7S colum at a flow ' rate of 11 ml/hr. The absorbance pro-
file was monitored at 280 nm using an ISCO u. v. monitor and 5. 9 ml
fractions were collected. During the gel filtration, the trypsin
inhibitor activity was resolved into two components which were pooled
separately, dialyzed against deionized water and lyophilized. In some
cases it was necessary to remove small amount of contaminants by
rechromatography over the same G-75 column.
The inhibitor B preparation obtained from G-75 column was resolved
by analytical isoelectrofocusing into two components with isoelectric
pH of 5. 3 and 7. However, further attempts to separate the two
components by ion-exchange chromatography on DEAE-cellulose (at pH 6.
in 10 rn phosphate buffer), and DEA-Sephadex A 25 (at pH 6. 2 in 20 rn
maleate buffer) were not successful.
(d) Determination of molecular wei ht b
y g
el filtration
The molecular weight of each inhibitor was estimated from their
elution positions on the G-7S column after calibration with pepsin (M.
35, 000) chymotrypsinogen (M. W. 25, 000), myoglobin (M. 17, 000) ,
ribonuclease A (M.W. 13, 700) and Aprotinin (M.W. 6, 500). The void
volume (Va) was determined empirically with blue dextran. The molecular
weight of each inhibitor was calculated from a plot of the log of the
molecular weights of the standard proteins against their ratio of the
elution volume (V ) to the void volume.
(e) Determination of the heat 'stabilit of tr sin inhibitors A and B
A series of tightly sealed 1. 5 ml eppendorf tubes each containing
27. 6 pmoles of trypsin inhibitor A or 29 pmoles of trypsin inhibi tor B
in 100 l of 20 rn tr is-HCl buffer pH 7. 0 were treated in a boiling
water bath for 5, 10, 20, and 30 minutes. The reaction tubes were
rapidly cooled on ice and centrifuged in a microcentrifuge to recover
any moisture that had condensed on the walls during the incubation.
Twenty-five microliters of each supernatant, was assayed for trypsin
inhibitory activity.
(f) The effect of the reducin ent dithiothreitol on the activities
of tr sin inhibitors A and B
To evaluate the effect of DTT on inhibitor activity, trypsin t i
inhibitor A (87. 175. 2 or 262. 8 pmoles) or trypsin inhibitor B (103,
206 or 309 pmoles) were diluted into 200 l of 20 rn tris-HCl buffer,
pH 7. 5 containing 2. 5 rn DTT. The tubes were flushed with nitrogen,
allowed to incubate for 60 minutes at room temperature, and 25 
aliquots were assayed for trypsin inhibitor acti vi ty.
(g)
Determination of the inhibi tor acti vi t of inhibitor s A and B
towards var ious ro teases
Representative examples of proteases from the aspartate, metallo,
serine and thiol protease families were used to assess the broad range
inhibitory property of trypsin inhibitors A and B. The assay conditions
selected for each protease is given in Table Each protease except
thrombin and plasmin was pre incubated for 10 minutes at 35 C with
either trypsin inhibitor A (18. 7 to 75. 9 pmoles) or inhibitor B (20.
to 82. 9 pmoles) in 500 l of buffer. Five hundred microliters of the
appropriate substrate was added and the incubation continued at 35
for the desired time. Reactions were terminated, the mixtures centri-
fuged and the increase in absorbance of each supernatant was measured
at 280 nm (hemoglobin) or 520 nm (Azocoll).
Plasmin was assayed as follows: porcine plasmin (approximately
38 CTA units, 23 pmoles) was preincubated with trypsin inhibitor A
for 10 minutes in 500 l of 0. 06 M sodium phosphate buffer, pH 7.
containing 0. 05 M lysine, 500 l of 1% casein solution in 0. 06 M sodium
phosphate buffer, pH 7. 4, was added and incubation continued for an
additional 30 minutes. ~e reaction was terminated and the absorbance
of the supernatant was read at 275 nm following centrifugation.
Thrombin was assayed as follows: thrombin (0. 2 NIH uni ts, approx.
2 pmoles) was preincubated at room temperature with either inhibitor
A (68 pmoles or 171 pmoles) or inhibitor B (86. 5 pmoles or 173 pmoles)
in a total volume of 20 l of 0. 017 M irnazole buffer, pH 7. 25. Three
T
a
bl
e 
4
C
o
n
di
 t
io
ns
 e
m
p
lo
ye
d 
fo
r 
th
e 
as
sa
y 
of
 p
ro
te
as
es
 u
se
d 
in
t
he
 s
pe
ci
fi
ci
ty
 s
tu
di
es
 o
f 
tr
yp
si
n 
in
hi
bi
to
rs
 A
 a
nd
 
Pr
ot
ea
se
Am
un
t o
f t
he
Su
bs
tra
te
B
uf
fe
r
In
cu
ba
tio
n
R
ea
ct
io
n
p
r
o
t
e
a
s
e
 
u
s
e
d
u
se
d
tim
e
t
e
r
m
in
at
ed
 b
y
(pm
ole
s)
(m
inu
tes
)
Ch
ym
ot
ry
ps
in
H
em
og
lo
bi
n
i +
20
 
1.
0 
ml
 o
f 
10
%
Ca
Cl
TC
A
El
as
ta
se
A
zo
co
ll
1.
0 
ml
 o
f 
30
%
a
c
e
t
ic
 a
ci
d
Pa
pa
in
H
em
og
lo
bi
n
i+
0.
 0
2%
1.
0 
ml
 o
f 
10
%
ED
TA
TC
A
Pe
ps
in
H
em
og
lo
bi
n
01
8 
If
1.
0 
ml
 o
f 
10
%
B
CI
Te
A
Su
bt
ili
sin
H
em
og
lo
bi
n
11
i
1.
0 
ml
 o
f 
10
%
B
PN
'
TC
A
Th
er
m
ol
ys
in
H
em
og
lo
bi
n
11
i
1.
0 
ml
 o
f 
10
%
TC
A
Tr
yp
sin
H
em
og
lo
bi
n
ii
+2
0 
mY
1.
0 
ml
 o
f 
10
%
Ca
Cl
TC
A
Pl
as
m
in
Ca
se
in
1.
5 
ro
l o
f
5 
If
 H
C1
0
Th
ro
m
bi
n
Fi
br
in
og
en
Bu
ffe
r i
1 
M 
tr
is
pH
 7
, 5
B
uf
fe
r i
v 
0.
06
 M
 p
ho
sp
ha
te
 c
on
ta
in
in
g 
0.
05
 M
ly
si
ne
. 
pH
 7
.
D
u
ff
er
 i
i 
0.
05
 M
 t
ri
s
,
 
p
H
 
8.
B
u
f 
fe
r 
v
01
7 
M
 im
id
az
ol
e
,
 
p
H
 
7.
D
u
ff
er
 i
ii
 0
.
05
 M
 t
ri
s
,
 
p
H
 
7.
)).,
hundred microliters of fibrinogen solution (0. 4% in 0. 017 M imidazole
buffer containing 0. 067% w/v CaC12) was added and the time at which the
first clot appeared was recorded as the end point.
(h) The effect of subtilisin BPN' on tr sin inhibitors A and B
To determine if the native trypsin inhibitors A and Bare suscept-
ible to proteolytic inactivation, 93. 8 pmoles of inhibitor A or 114.
pmoles of inhibitor B were incubated for 20 minutes at 35 C in 50 mM
tris-HCl buffer, pH 7. 5 with 36. 72. 109. 1 or 145. 5 pmoles of sub-
tilisin BPN' At the end of the incubation, subtilisin was inactivated
by boiling the mixture for 10 minutes. The tubes were allowed to cool
in an ice bath, centrifuged and 25 l aliquots of the supernatant were
assayed for trypsin inhibitor activity.
( i) The ultraviolet absor tion s ectra of tr sin inhibitors A and B
Trypsin inhibitor A or inhibitor B were dissolved in double dis-
tilled deionized water at a concentration of 2. 307 mg/ml and 0. 151 mg/ml
respectively, filtered through a Millipore 0. 22 m type MF filter and
the ultraviolet absorption spectra were recorded between 230 and 340 nm
using a Gilford 250 spectrophotometer.
(j)
Character ization of the lexes formed between tr sin
inhibitor A and tr sin and ch motr sin
To evaluate whether Manduca sexta hemolymph trypsin inhibitors A
and B formed stable complexes with trypsin, samples of trypsin inhibi-
tor A (11 nrnles) or inhibitor B (33. 7 nrnles) were incubated at 35
with 8. 5 nmoles of trypsin in a total volume of 200 1 of 20 mM tr is-
HCl buffer, pH 7. After allowing 15 minutes for the assoc ation of
the inhibitors with trypsin, the mixtures were chromatographed at 4
on a Sephadex G-IOO column (0. 9 x 23 cm) equlibrated with tr is-HCl
buffer, pH 7. 5, containing 0. 5 M NaCl. The absorbance of each
fraction (1. 4 ml) was measured at 280 nm and 25 l aliquots of each
fraction was used to assay trypsin inhibitor activity using BAPNA as
descr ibed . The Sephadex G-IOO column used was calibrated with bovine
serum albumin (M. W. 67, 000), ovalbumin (M.W. 44, 000), chymotrypsinogen
(M. W. 25, 000) and lysozyme (M. W. l4, 400).
~e stoichiometr ies for the association of trypsin and chymotrypsin
with trypsin inhibitor A were determined by evaluating the extent of
complex formation at various inhibitor concentrations using direct in-
hibition measurement and by the use of active site titrants. Stoichio-
- metr ic studies were performed only on inhibitor A, since inhibitor B
was found to resolve on isoelectrofocussing into two components with
isoelectric pH of 5. 4 and 7. Since it is not known whether both com-
ponents of inhibitor B display equal affinity towards trypsin, stoichio-
metr ic studies were not performed on the inhibitor B preparation.
Trypsin (50. 9 pmoles) was incubated with inhibitor A (0 to 44.
pmoles) at 35 C for 10 minutes in 500 l of tris-HCl buffer (0. 2 M, pH
3) containing 40 rn CaC12. Residual trypsin activity was determined
by adding 500 l of an aqueous solution of BAPNA (final concentration 1
rn) and continuing the incubation for an additional 30 minutes.
reaction was terminated by addition of 500 l of 30% v/v acetic acid,
and the absorbance at 410 nm was recorded. In a similar manner, 520
pmoles of chymtrypsin was pre incubated with varying amounts of inhib-
itor A (0 to 503 pmoles) for 10 minutes at 35 C in a reaction volume
500 l of tr is-HCl buffer, pH 7. 8, containing 20 rn CaC12.
residual chymotrypsin activity was measured using glutaryl-L-
phenylalanyl p-nitroanilide, GPNA (final concentration 1 ro), and the
liberated p-nitroaniline was quantitated as described for trypsin.
The stoichiometry was evaluated by plotting the fractional
activity, vi/va (the ratio of activity in the presence of inhibitor to
the activity in the absence of inhibitor) against the molar ratio of
inhibitor A to trypsin or chYmtrypsin (see Results, page 71).
Active sites titrations were performed as follows: varying amounts
of trypsin inhibitor A (3. 13 to 15. 7 nmoles) were incubated at room
temperature for 5 minutes with 22 nmoles of trypsin in a total volume
of 1. 0 ml of 0. 07 M veronal buffer, pH 8. 3, containing 15 rn CaC12.
- Ten microliters of a solution of p-nitrophenyl p' guanidinobenzoate
(NPGB, 0. 01 M in dimethylformamide) was added, and the initial "burst"
of p-nitrophenol released due to rapid formation of the acyl-enzyme
intermediate was measured using the molar extinction coefficient for p-
nitrophenol of 16, 595 at 410 nm and pH 8. 3 (71). Similar ly, 0. 286 to
43 nmoles of trypsin inhibitor A was permitted to complex at room
temperature with 1. 49 nmoles of chymotrypsin in a total volume of 1.
ml of tris-HCl buffer, 0. 05 M, pH 7. One hundred microli ter s of 0.
rn 4-methylumbelliferyl p-N, N, N, trimethylarnniumcinnamate (MUTMAC,
final concentration 10 M) was added, and the immediate burst of
fluorescence at 450 nm was recorded with excitation set at 360 nm.
amount of 4-methylumbelliferone liberated was calculated from a standard
curve prepared using recrystallized 4-methylumbelliferone. Plots of
the concentration of the active (i. e. uninhibited) protease against the
ratio of trypsin inhibitor A to the total protease were used to cal-
culate the stoichiometry of the reactions (see Results, page 74).
(k) Estimation of inhibition constants for the inhibition of
sin and ch otr sin b sin inhibi tor A
The inhibition constants (Ki) for inhibition of trypsin and
chymotrypsin by trypsin inhibitor A were evaluated by the method of
Meyers-Cha (72). This method requires the initial calculation of I501
the concentration of inhibitor required to cause 50% inhibition of
enzyme activity, at various enzyme concentrations. In order to deter-
mine ISO values for trypsin inhibition, trypsin (50. 9, 101. 8, or 151.
pmoles) was preincubated with 0 to 98. 1 P moles of trypsin inhibi tor A
and residual trypsin activity was assessed using BAPNA as the substrate
as described previously (page 30). The fractional activity, i. e., the
ratio of the activity in the presence of inhibitor (vi) to the activity
in the absence of inhibitor (v )' was plotted against the inhibitor
concentration, and the inhibitor concentration required to produce 50%
inhibition (I O) was evaluated. From the ISO values, the inhibition
constant (Ki) was obtained as described under Results (page 77).
In a similar set of experiments, chymotrypsin (0. 393, 0. 786,
179, and 1. 572 nmoles) was preincubated with 0 to 1. 005 nmoles of
trypsin inhibitor A, and the residual chymtrypsin activity was
measured using GPNA as the substrate as described above (page 45).
results were analyzed in the same way as described for trypsin (see
Resul ts, page 79).
(1) Do tr sin and ch otr sin bind to the same si te on inhibi tor 
Because trypsin inhibitor A was found to inhibit both trypsin and
chymotrypsin, it was of interest to determine whether inhibitor A
complexed with one protease would still inhibit the other protease.
Accordingly, two sets of reaction mixtures containing 0. 57 nmoles of
trypsin were pre incubated for 10 minutes at 350 C with 0. 37 nmoles of
trypsin inhibitor A in 0. 05 M tr is-HCl buffer, pH 7. Trypsin was
added in excess to ensure that inhibitor A was in complex with trypsin.
After preincubation, varying amounts of chymtrypsin (0. 43 to 1.
nmoles) were added and the incubation continued for 10 minutes. One
set of reaction mixtures were assayed for trypsin activity using BAPNA
as the substrate and the second set of reaction mixtures were assayed
for chymotrypsin activity using GPNA as the substrate. In an alternate
set of experiments, 1. 05 nmoles of chymotrypsin was pre incubated with
47 nmoles of trypsin inhibitor A using the same conditions described
for trypsin. At the end of the incubation varying amounts of trypsin
(0. 51 to 2. 03 nmoles) were added and the incubation continued for 10
minutes. One set of reaction mixtures was assayed for chymotrypsin
activity using GPNA as the substrate and the other set was used for
trypsin assay using BAPNA as the substrate.
Studies on the activation of prophenoloxidase in the
hemolymph of Manduca sexta
(a) The effect of the serine rotease inhibitor, diiso hos-
hofluoridate, on the a earance of henoloxidase activit
hemolymph of Manduca sexta
To ascertain whether activation of the prophenoloxidase of Manduca
sexta hemolymph was due to activity of a serine protease in a manner
analogous to Bomb mori , the effect of DFP on the activation of pro-
phenoloxidase was studied. Fi ve hundred microli ter s of hemolymph from
the larvae of Manduca sexta in the final ins tar was mixed with 500 
of 0. 1 M sodium phosphate buffer, pH 7. 0, containing 0. 1% SDS and 10
M DFP. SDS is necessary for lysis and release of the hemocyte constit-
uents essential for prophenoloxidase activation. Fi ve microli ter
aliquots were withdrawn at 5, 10, 15, 20, 25, and 30 minutes, diluted
with 995 l of 0. 1 M phosphate buffer containing 0. 2% L-dopa and the
absorbance increase at 475 nm due to dopachrome formation was measured.
Hemolymph diluted with phosphate buffer lacking DFP served as a control.
One unit of phenoloxidase activity was defined as the amount of enzyme
which causes and increase in absorbance of O. Ol/min at 475 nm.
(b) The effect of tr sin inhibitors A and B on the activation of
henoloxidase in a hemoc te l sate from Manduca sexta
Hemocyte suspension prepared as described on page 37 was used for
this exper iment. Cells from a 400 l aliquot of the hemocyte suspens-
ion (approximately 4 X 107 cells) were pelleted and resuspended in 60
l of buffer G, 10 mM cacodylate buffer, pH 7. 0, containing 5 mM CaC12'
(lysate C), or in 60 l of buffer G containing either 8. 6 M trypsin
inhibitor A (lysate A), or 27. M trypsin inhibitor B (lysate B).
Each cell suspension was sonicated (3 x 10 second bursts), centr ifuged
. at 12, 000 x g for 3 minutes and the supernatant was used in the prophen-
oloxidase activation exper iments descr ibed below.
Prophenoloxidase was activated and assayed as follows: 10 l of
lysate C was incubated for 1 hour at room temperature with 0. 025%
laminar in and 0. 05 M MgC12 in a total volume of 800 Prophen-
oloxidase in lysates A and B were activated similarly but the acti-
vation was performed in the presence of 8. M trypsin inhibitor A in
the case of lysate A and 27. 4 trypsin inhibitor B in the case of
lysate B. After incubation, 500 l of each reaction mixture was mixed
with 500 l of L-Dopa (2 g/liter in buffer G) and the absorbance at 475
nm was recorded after incubating at room temperature for 3 minutes.
='"
Does Manduca sexta hemolymph contain a system resembling the
alternative complement pathway?
(a) The effect of Manduca sexta hemolymph and pur ified trypsin
inhibitors A and B on activation of the alternative pathway of
complement
The rabbit erythrocyte hemolytic assay (page 35) was used to
ascertain the effect of components in the hemolymph of Manduca sexta
and purified trypsin inhibitors A and B on the activity of the human
alternative complement pathway. Br iefly, 25 l of fresh frozen Manduca
sexta hemolymph was incubated at 37 C with 25 l of a 1: 3 dilution of
human serum and 10 l (3. Sx 107 cells) of rabbit erythrocytes in a
tot.al volume of 150 At the end of the incubation per iod, 1 ml of
ice-cold GVE was added, the reaction mixture centr ifuged at 1, 200 x g
and the absorbance at 414 nm of the supernatant was determined.
Controls in which GVS replaced either hemolymph or serum were run in
paralleL
To examine the effects of supernatant of heat- inactivated hemolymph
and of the purified inhibitors A and B on activation of the alternative
complement pathway, assays similar to the one descr ibed above was used
except that fresh frozen hemolymph was replaced by the supernatant of
hemolymph boiled for 15 minutes or by inhibitor A (0. 43 nmoles) or
inhibitor B (1. 67 nmoles).
f;,
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(b) Investi ations to assess whether the hemolymph of Manduca sexta
contains factors functionall analo ous to human com lement
factor s D and B
To assess whether Manduca sexta hemolymph contains factors capable
of substituting for human factors D and B, 25 l of human RD or RB sera
were mixed with 3. 5 x 107 rabbit erythrocytes and fresh frozen Manduca
sexta hemolymph (10 l for RD serum and 8 l for RB serum) in a total
reaction volume of 150 A control where GVBS replaced RD or RB
serum was run in parallel. The reactions were incubated at 37 C for 1
hour and the extent of hemolysis quantified as described.
(c) Exper iments to assess human factor B cleavage by factors present
in the hemolymph of Manduca sexta
It is possible that the hemolymph of Manduca sexta may contain a
protease capable of cleaving human complement factor B and render it
unavailable for participating in complement reactions. To assess
whether such a protease is present in Manduca sexta hemolymph, 100 
of fresh frozen human serum containing 10 rn MgC12 was incubated with
10 l of fresh frozen hemolymph at 37 C for 1 hour. Control reactions
were run in parallel in which hemolymph was replaced by 1 mg or 10
mg/ml E. coli lipopolysacchar ide in GVS, GVS alone, and the supernatant
of hemolymph immersed in boiling water bath for 15 minutes. coli
lipopolysaccharide is a natural activator of the alternative complement
pathway which results in the cleavage of factor B to Ba and Bb fragments.
In separate set of experiments, purified factor B (92. g) was
incubated at 37 C for 1 hour with 10 l of fresh frozen hemolymph in
100 l of 0. 1M veronal buffer, pH 7. 5 in the presence or absence of 10
rn MgC12. +2 ions are required for factor B cleavage by factor D.
At the end of the incubation per iod 15 l aliquots of each reaction
mixture was immunoelectrophoresed as descr ibed (page 32).
CHAPTER II 
RESULTS
Measurement of tr sin inhibitor activit in the hemolymph of
Manduca sexta dur larval and al sta
Trypsin inhibitory activity in the hemolymph of Manduca sexta
was found to decrease as the animals passed from the larval stage to
the pupal stage (Fig. 7). The hemolymph of the ear ly pupae had approx-
imately 50% of the activity found in the larval hemolymph, while the
hemolymph from late pupae had only a tenth of the activity of that of
larvae. The total hemolymph trypsin inhibitory activity is likely to
follow a similar pattern because the hemolymph volume also decreases
during the pupal stage (73). Higher amount of trypsin inhibitory
activity in the larval hemolymph suggests that these inhibitors have
important functions in the larval hemolymph. For example, the
hemolymph trypsin inhibitors could potentially regulate hemolymph
prophenoloxidase activation since the latter enzyme is activated by a
trypsin-like protease. Unregulated activation of prophenoloxidase can
have deleter ious consequences. Phenoloxidase can cause improper
sclerotization thus impairing the mechanical properties of larval
cuticle. Further, melanin deposition on tissues by phenoloxidase can
stimulate phagocytic cells, thereby affecting tissue integr i ty.
, !
Larval
hemolymph, vitro, darkens slowly (due to the endogenous activation
of prophenoloxidase) when compared to the pupal hemolymph suggesting an
inverse relationship between hemolymph trypsin inhibitory activity and
380
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Fig. 7. Quantitation of trypsin inhibitory activity
in the hemolymph of Manduca sexta during
larval and pupal stages.
prophenoloxidase acti va tion. In order to examine the effects of hemo-
lymph trypsin inhibitors vitro, it is necessary to purify them.
Since the larval hemolymph contained higher trypsin inhibitory acti vi ty,
this was chosen for inhibitor isolation.
Isolation and structural anal sis of tr sin inhibitors
from the hemolymph of Manduca sexta
Purification and biochemical characterization of two trypsin
inhibitors from the hemolymph of the larval stage of Manduca
sexta.
The protocol for the purification of trypsin inhibitors from
Manduca sexta hemolymph is summar ized in Fig. Preliminary exper i-
ments demonstrated that the trypsin inhibitory activity in hemolymph
- was stable even at pH 1. Since addition of perchloric acid to a final
concentration of 0. 7% precipitated 90% of the hemolymph proteins
while all of the trypsin inhibitory activity remained in solution acid
precipi tation with perchlor ic acid was incorporated as the initial step
in the inhibitor pur ification scheme. Pr ior to trypsin-Sepharose
affinity chromatography the trypsin inhibitors in the supernatant of
perchloric acid-treated hemolymph were concentrated by adding ammonium
sulfate to 90% saturation. Manduca sexta hemolymph trypsin inhibitors
adsorb tightly to trypsin-Sepharose, and 0. 1 M HCl containing 0. 75 M
NaCl (pH 1. 5) was necessary for the desorption of the bound inhibitors.
The trypsin-Sepharose elution profile is presented in Fig. 9. Approxi-
mately 60% of the applied activity was recovered from trypsin-Sepharose
affinity gel. The reason for the relatively low yield of trypsin
inhibitors is not clear. Since the trypsin-Sepharose wash fractions
were not found to contain any trypsin inhibitory activity, the unre-
PURIFICATION PROTOCOL
CRUDE HEMOLYMPH
r 0. 7% perchloric
PRECIPITATE SUPERNATAN
90% amonium SUl
PRECIPITATE SUPERNATANT
discarded) 
acid
trypsin Sepharose
UNBOUN BOUN
Sephadex G
INHIBITOR A INHIBITOR
Fig. 8. Flowchart illustrating the protocol adopted
to purify trypsin inhibitors from Manduca
sexta hemolymph.
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Fig. Chromatographic prof ile of trypsin inhibitor
activity on a trypsin-Sepharose affinity
column.
covered trypsin inhibitory activity perhaps remains bound to the
trypsin- Sepharose gel. Further attempts to recover trypsin inhibitory
activity by eluting with 0. 1 M HCl containing 1. 5 M NaCl or 0. 1 M
ammonium acetate adjusted to pH 3. 0 with glacial acetic acid did not
increase the yield. The eluate from trypsin-Sepharose affinity
chromatography was further resolved into two components with molecular
weights of 13, 700 and 8, 000 by gel filtration on Sephadex G-75 (Fig.
lO, lOa). A summary of the isolation procedure for a 315 ml volume of
hemolymph preparation is outlined in Table 
Inhibitors A and B after gel filtration on a Sephadex G-7S
colum were of high purity since each gave rise to a single protein
band on SDS-polyacrylamide gel electrophoresis under reducing as well
as non-reducing conditions (Fig. 11 and 12). Isolectrofocusing on
polyacrylamide gels containing pH 3-10 ampholytes focused inhibitor A
as a single band bf isoelectr ic point 5. 7. However, inhibitor B could
be resolved into two components with isolectr ic points of 7. 1 and 5.
Molecular weights estimated by SDS-polyacrylamide gel electrophoresis
under non-reducing conditions gave values of 15, 000 for inhibitor A and
500 for inhibitor B. This agrees with molecular weight estimated by
gel filtration on Sephadex G-75. However on SDS-page under reducing
conditions inhibitor A migrated as a single component with a calculated
molecular weight of 8, 300, and inhibitor B migrated with a calculated
molecular weight of 9, 100, suggesting that inhibitor A was composed of
two identical subunits.
Purified inhibitors A and B could be stored frozen at -20 C for
a minimum of six months without any detectable loss of activity. Both
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Fig, 11
17000
14400
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2500
SDS-Polyacrylamide slab gel electrophoresis of
purified trypsin inhibitors A and B in the
absence of mercaptoethanol,A: Inhibitor A B: Inhibitor B
S: Molecular weight standards
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Fig, 12 SDS-Polyacrylamide slab gel electrophoresis of
purified trypsin inhibitors A and B in the
presence of mercaptoethanol,A: Inhibitor A B: Inhibitor B
S: Molecular weight standards
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inhibitors A and B are stable for at least 30 minutes at 100 How-
ever incubation of either inhibitor A or B in the presence of 2. 5 ro
dithiothreitol at room temperature for 1 hour resulted in the complete
loss of their activity even in the absence of a denaturant.
Fig. 13 shows the effect of subtilisin BPN' on the acti vi ty of
inhibi tors A and B. A progressive loss of activity is observed with
increasing concentrations of subtilisin BPN' indicating that inhibitors
A and B are equally susceptible to proteolytic inactivation by
subtilisin BPN' Alternative possibilities such as complex formation
between inhibitors A or B and subtilisin BPN' or the proteolysis of the
trypsin used for quantitation of inhibitor activity by subtilisin BPN
are unlikely because subtilisin BPN' was denatured at the end of pre-
incubation with inhibitors A or B by heating the reaction mixtures at
100 C for 10 minutes. The trypsin inhibitory activity of 93. 8 pmoles
of inhibitor A or 114. 1 pmoles of inhibitor B is completely destroyed
in 20 -minutes by 145. 5 pmoles of subtilisin BPN'
The ultraviolet absorption spectra of both inhibitor A and inhib-
itor B (Fig. 14 and 15) demonstrated a character istic protein spectrum
with an absorption maximum at 277 nm.
The ability of trypsin inhibitors A and B to inhibit a var iety
of commercially available proteases from bacter ia, plant and animal
origin were evaluated. The results are tabulated in Table Both
inhibitor A and inhibitor B inhibit trypsin, chymotrypsin, plasmin, and
thrombin. Somewhat higher concentrations of inhibitor B were required
to inhibit both trypsin and chymotrypsin than were required for inhib-
itor A. Complete inhibition of trypsin and chymotrypsin (52 pmoles
a: I
INHI81TOR A
31. 145.5
pmol..
INHI81TOR 8
32.3 101. 145.72. 10.
SUBTILISIN BPN'
72.
SUBTILISIN BPN' pmol..
Fig. 13 The inactivation of trypsin inhibitory activity
of inhibitors A and B by subtilisin BPN'
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230 260
WAVELENGTH (nm)
290 320
Fig. 14. Ultraviolet absoption spectrum of trypsin
inhibi tor 
a: 0.
220 244 268 292 316 340
WAVELENGTH (nm)
Fig. 15 Ultraviolet absorption spectrum of trypsin
inhibitor 
Table
Effect of trypsin inhibitors A and B on various proteases
Protaase
(pmole)
Activit with inhibitor A 
18. 9 39. 8 75,(pmole) (pmole) (pmole)
Activit with inhibitor B 
%)*
20. 7 41.4 82,(pmole) (pmole) (pmole)
. " - -
J=-
Ii.ct':, Serine
Trypsin (52) 25.
64,
18.
Chymotryps in (56) 14.
Subtilisin BPN' (73) 100 100 100
106
100
Elastase (77) 111 100
art
Pepsin (57) 100 104 106 100
Papain (86) 105 105 105 100
Metallo
Thermolysin (58) 100
Plasma serine roteases 68.(pmole) 171. 0(pmole)
Plasmin (23) 49.
Thrombin.. (2.
Act i v i ty in the absence of inhibitor was taken as 100%.
32.
100
104
104
100
100
86.(pmole)
39,
100
100
100
173.(pmole)
The clotting time did not increase linearly with inhibitor amount
, but the amountclot formed was less in the presence of inhibitors 
i\ and B.
, !
: i
: I
each) was observed at a concentration of 39. 8 pmoles of inhibitor A,
whereas with 41. 4 pmoles of inhibitor B 90% and 68% of the acti vi ties
of trypsin and chymotrypsin, respectively, were inhibited. Plasmin (23
pmoles) was completely inhibited by 171 pmoles and 173 pmoles,
respectively, of inhibitor A and inhibitor B, however, the same amount
of inhibitors A and B inhibited only 50% of the activity of 2. 2 pmoles
of thrombin. Neither trypsin inhibitor A nor B inhibited the bacterial
ser ine protease subtilisin BPN' or porcine elastase. Each also failed
to inhibit pepsin (an aspartyl protease), papain (a sulfhydryl
protease) and thermolysin (a Zn metalloprotease). Therefore, it
appears that both inhibitor A and inhibitor B have specificity for
chymotrypsin and trypsin-like ser ine proteases.
Studies on the complex formation of trypsin inhibitor A with
trypsin and chymotrypsin
(a) Demonstration of the formation of com lexes b sin
inhibitors A and B with bovine tr sin.
To demonstrate that inhibitors A and B form complexes with
trypsin, each inhibitor was incubated with trypsin and subjected to
gel filtration on a Sephadex G- IOO column. The elution profiles of
inhibitors A and B and their respective complexes with trypsin are
presented in Fig. 16 and 17. Inhibitor A eluted at a position corre-
sponding to a molecular weight of 20, 000 daltons and inhibitor B
eluted with a molecular weight corresponding to 15, 000 daltons. The
molecular weights calculated for trypsin inhibitors A and B by gel
filtration on G-IOO column were higher than the molecular weight
calculated by gel filtration on Sephadex G-7S column (M. W. of inhibitor
A was 13, 700 and the M.W. of inhibitor B was 8, 000). The trypsin-
0 q
lri 
E 0.035
10 
Elution Volume (ml)
Fig. 16. Sephadex G-100 elution profile of trypsin
inhibi tor A and the complex formed between
trypsin (8. 5 nmoles) and inhibitor A (11 nmoles).
o 0 o 0 o 0 
Jf: Jt 
.. 
' ;: l
; k
' I
, ,. -
C ,
. :M 
. :
- 0. 40 E
g 0.
, ,.-,
80 :;
,; l'
40 -2
/  \!
/f:'
'''
Elution Volume (ml)
Fig. 17 Sephadex G-100 elution profile of trypsin
inhibi tor B and the complex formed between
trypsin (8. 5 nmoles) and inhibitor B (33. nmoles) .
inhibitor A complex and the trypsin-inhibitor B complex eluted at
posi tions of molecular weight of 47, 000 daltons and 38, 000
daltons respectively. Since trypsin eluted with a molecular weight of
23, 000 daltons on Sephadex G-IOO, the molecular weights of the
complexes suggest that 1: 1 molar complexes are formed between both
inhibitors and trypsin.
(b) Determination of the stoichiometr for the reaction of tr sin
inhibitor A with tr sin and chymo sin.
The stoichiometr ies between inhibitor A and trypsin and chymo-
trypsin were evaluated in two ways. In the first method, 50. 9 pmoles
of trypsin was incubated individually with 0 to 44. 2 pmoles of
inhibitor A and the residual trypsin activity was quantitated using
BAPNA as the substrate. Similarly, 520. 0 pmoles of chymotrypsin was
incubated with 0 to 503. 0 pmoles of inhibitor A and the residual
chymotrypsin activity was quantitated using GPNA. To obtain the
stoichiometry between inhibitor A and trypsin, relative trypsin
activity, i. e., the ratio of trypsin activity in the presence of
inhibitor A (vi) to the activity in the absence of inhibitor A (v ) was
plotted against the molar ratio of inhibitor A to trypsin (based on a
molecular weight of 15, 000 for inhibitor A and 24, 000 for trypsin and
chymotrypsin) (Fig. 18). Complete inhibition of trypsin was observed
at an inhibitor A/trypsin ratio of 1. 07 indicating a 1:1 stoichiometric
complex between trypsin and inhibitor A. Similar ly, a plot of the
relative activity (vi/v ) against the molar ratio of inhibitor A to
chymotrypsin (Fig. 19) showed that complete inhibition of chymotrypsin
o-.
"""1;
,yo",,
."I
INHIBITOR A/TRYPSIN (MOLE/MOLE)
Fig. 18. Plot of v. Iv against the molar ratio of
trypsin inhibitor A to trypsin.
;1 \.
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. f INHIBITOR A/CHYMOTRYPSrN (MOlElMOLE)
Fig. 19. Plot of v. /v against the molar ratio of1. 0
trypsin inhibitor A to chymotrypsin.
was observed at an inhibitor A/chymotrypsin molar ratio of 1.
indicating that chymotrypsin also formed a 1: 1 stoichiometr ic complex
with inhibitor A.
In an alternate method for calculating the stoichiometries, 22
nmoles of trypsin was allowed to complex individually with 3. 13 to 15.
nmoles of inhibitor A and the free trypsin was determined using the
active site titrant NPGB. Likewise, l. 49 nmoles of chymotrypsin was
complexed individually with 0. 29 to 1. 43 nmoles of inhibitor A and the
free chymotrypsin was quantitated using MUTMAC as the active site
titrant. The ratio of free trypsin at each inhibitor concentration
with the total amount of trypsin (expressed as per cent) was plotted
against the ratio of inhibitor A/trypsin (Fig. 20). The extrapolated
value for 100% trypsin inhibition was calculated as 0. 94 moles of
inhibitor A/mole of trypsin. Likewise, the plot of free chymotryps 
at various concentrations of inhibitor A (expressed as per cent of
chymotrypsin concentration in the absence of inhibitor A) against
inhibitor A/chymotrypsin molar ratio (Fig. 21) gave a stoichiometric
value of 0. 91 for 100% chymotrypsin inhibition. Thus inhibitor A forms
1:1 stoichiometric complexes with both trypsin and chymotrypsin.
isoelectrofocusing, inhibitor B was resolved into two components with
pIs of 5. 3 and 7. Attempts to separate these components by ion-
exchange chromatography on DEAE cellulose and DEAE-Sephadex were not
successful. Since it is possible that each component could have
different affinity towards trypsin and chymotrypsin, stoichiometric
studies and the estimations of Ki values were not performed with
inhibitor B.
. -
100
INHIBITOR A/TRYPSIN (MOLE/MOLE)
Fig. 20. Plot of the concentrations of uncomplexed
trypsin against the molar ratio of trypsin
inhibi tor A to trypsin.
;; 100
Do 50
iI'-
';'
INHIBITOR A/CHYMOTRYPSIN (MOLEIMOlE)
Fig. 21. Plot of the concentrations of uncomplexed
chymotrypsin against the molar ratio of
trypsin inhibitor A to chymotrypsin.
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(c) Estimation of the inhibition constant (Ki) for the reactions of
inhibi tor A with trypsin and chymotrypsin
Polypeptide protease inhibitors generally exhibit high affinity
for their respective proteases. As a result, most of the inhibitor
added to free protease is immediately bound. The classical Lineweaver-
Burk method for the estimation of inhibition constants, which assumes
that a significant change in free inhibitor concentration does not
occur, cannot be used for the study of such high affinity inhibitors.
Goldstein (74) has derived a general equation which describes the
behaviour of high affinity inhibitors (equation 
It = (v /vi - 1) Ki + (1 - vi/vo)Et (1)
where It is the total inhibitor concentration, Et is the total enzyme
concentration, Ki the inhibitor dissociation constant, and v
a and vi
are the velocities of catalytic reaction in the absence and the
presence of the inhibitor, respectively. Many derivatives and
transformations of this equation have been published (72, 75, 76). One
such derivation which yields Ki in a simple and accurate way is that of
Meyers and Cha (72, 75) (equation 2).
ISO = Ki + Et/2 ( 2)
where ISO is the concentration of the inhibitor which gives 50%
inhibition of the enzyme activity. A plot of the ISO values determined
at several enzyme concentrations against the total enzyme concentration
yields a straight line plot wi th the ordinate intercept equal to Ki
(72) .
Fig. 22 is a plot of the ISO values of the reaction between
trypsin and inhibitor A against the respective trypsin concentrations.
Ir-
100
==-
lit
100 200
TRYPSIN CONCENTRATION x 10
Fig. 22 Plot of I50 values of trypsin inhibi tion
by inhi bi tor A as a funct ion of tryps 
concen t rat ion.
It was assumed that inhibitor A inhibits both trypsin and chymotrypsin
ii- competitively. From the plot, a Ki value for inhibitor A binding to
trypsin was estimated to be 1. 45 x 10-8 M. A similar plot of ISO
values of the reaction between chymotrypsin and inhibitor A against
e:- chymotrypsin concentrations (Fig. 23) gave a Ki value of 1. 7 x 10-8 M
for inhibitor A-chymotrypsin interaction.
Since inhibitor A inhibits both trypsin and chymotrypsin, two
operationally distinguishable situations can ar ise. The proteases can
either compete for the same inhibitor site, or they can be simul-
taneously and independently inhibited at different si tes on the
inhibi tor. Since inhibitor A is a dimer, the latter is a distinct
possibili ty. In order to distinguish between these two si tuations,
reactions were carried out in which inhibitor A was fUlly complexed
wi th excess trypsin and the complex was added to var ious amounts of
chymtrypsin. The results are presented in Fig. 24. Reaction of
inhibitor A- (0. 37 nmoles) with varying amounts of chymotrypsin (0. 43 to
7 nmoles) resulted in the inhibition of chymotrypsin activity
(control, Panel A) However, when the same experiment was performed
with inhibitor A preincubated with 0. 57 nmoles of trypsin to permit
total complex formation, the reaction mixture demonstrated no
inhibitory activity towards chymtrypsin (Panel B). In an alternate
experiment, 0. 47 nmoles of inhibitor A was reacted with trypsin (0.
to 2. 03 nmoles) and the residual trypsin activity was quantitated. The
results, Fig. 25, Panel A, shows that the trypsin activity was
inhibi ted. However when the same amount of inhibitor A (0. 47 nmoles)
was complexed with 1. 05 nmoles of chymotrypsin, and then allowed to
"i.
j'-
100
100 200
CHYMOTRYPSIN CONCENTRATION 
Fig. 23 Plot of 1
50 values of chymotrypsin inhibition
by inhibitor A as a function of chymotrypsin
concentration.
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react with trypsin, no inhibitory activity towards trypsin was observed
(Fig. 25 Panel B) Taken together, these results demonstrate that once
, a complex is formed between inhibitor A and either trypsin or chymo-
trypsin, the complex is not displaced by the other protease. Further-
more, these results indicate that inhibitor A does not have two
independent sites for trypsin and chymotrypsin.
Amino terminal sequence analysis of inhibitors A and B
from the hemolymph of Manduca sexta
(a) Amino acid com sition anal sis and peptide ma of hemolymp
inhibitors A and B.
~e amino acid compositions of inhibitors A and B are listed in
Table 7. The differences in the amino acid composition suggest that
inhibitor A and inhibitor B are both unique. To further compare
inhibitors A and B, each reduced and S-carboxymethylated protein was
digested with trypsin-TPCK and peptide mapping was performed by HPLC.
The tryptic peptide patterns obtained (Fig. 26 and 27) clearly demon-
strate that inhibitors A and B are different.
(b) Amino terminal amino acid se uences of sin inhibitors A and B.
Knowledge of the pr imary structures trypsin inhibitors A and B
essential in order for comparisons to be made with the inhibi tor s
isolated from other sources. Such compar isons should be useful not
only in understanding the physical interactions of inhibitors A and B
with trypsin but also with serine proteases in general. The amino
terminal amino acid sequences of inhibitors A and B were obtained using
a Beckman sequenator which had been modified for protein microse-
quencing. Fifty-six amino terminal residues were identified for
Table 7
Amino acid compositions of trypsin inhibitors A and 
Amino acid lnhibi tor lnhibi tor
Mole Res idues / Mole Res i dues /
mole* mo le*
Ala 15. 11.
Arg
Asn+Asp 12. 10.
Cys
Gln+Glu 14. 16.
Gly 12. 58 13 . 95
His
lIe
Leu
Lys
Met
Phe
. .
:. I Pro
Ser
Thr
" t- Trp
Tyr
Val
;, 
Based Argjmole Not determined
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inhibitor A and fifty-three amino terminal residues were elucidated for
inhibitor B. This data is presented in Fig. 28. Interestingly,
inhibitor B was heterogenous at cycle 20 (Phe and Tyr) and at cycle 33
(Thr and Gly), which is consistent with the presence of two isoelectr 
forms demonstrated by isoelectrofocusing. 
Compar isons of the amino terminal amino acid sequences of the
hemolymph inhibitors A and B with the sequences of other known serine
protease inhibitors revealed that both inhibitors A and B were
homologous to the BPTI family of trypsin inhibitors (Fig. 29). The
conserved amino acid residues in all BPTI-like proteins have been boxed
in Fig. 29. Accordingly, BPTI enumeration has been used throughout
this thesis in discussions on the sequence of inhibitors A and B. When
compared to BPTI, inhibitor A has 17 additional amino acid residues at
the amino terminal region. ~erefore, of the fifty-six known residues
of inhibitor A only 39 residues correspond to BPTI-like protease
inhibi tor s. Inhibi tor A and BPTI are identical at 14 of 39 (36%)
positions. If conservative substitutions are considered, nearly 50% of
the amino acids are homologous. In the case of inhibitor B, 19 of the
53 residues (36%) are identical with BPTI. If conservative
substi tutions are considered, 50% of inhibitor B is homologous to BPTI.
Inhibitors A and B share 24 of the 38 commn residues.
Lys 15 has been shown to be the specificity conferr ing residue in
BPTI (40). ~e peptide bond between Lys 15 and Ala 16 of BPTI has been
designated as the reactive site peptide bond. Both inhibitor A and
inhibitor B have Arg at the position corresponding to Lys 15 of BPTI.
Since Arg and Lys are both basic amino acids which are recognized by
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Manduca sexta inhibitor A
10 AGLYKPPNN I ESENEVYTGN I CFLPL
EDICSLPPManduca sexta inhibitor B
Bovine pancreatic inhibitor RPDFCLEPP
Bovine colostrum inhibitor FQTPPDLCQLPQ
KQNGRDICRLPPTurt Ie egg whi te inhibitor
Russell viper venom inhibitor HDRPTFCNLAP
Snail isoinhibi tor K EGRPSFCNLPA
INGDCELPKSea anemone inhibi tor10 20 30 40 EVGVCRALFFRYGYDPA I KACXEFMYGGXQ-- 
-- -- - -- --
EVGPC RAG FL A YY S E LN KCKLFaYGGCQGNE NNFET LQA
YTGPCKARIIRYFYNAKAGLCQTFVYGGCRAKRNNFKSAED
A RGPC KAA LLRY FYN S T S NACEPFTYGGCQGNNNN F E TT E M
EQGPCKGR I PRYFYNPASRMCE SF I YGGCKGNKNNFKTKAE
E S G R C K G RIP R Y F Y N PAS R ,K C K V F F Y G G C G G NAN N F E T R D E
ETGPCKASFRQYYYNSKSGGCQQF I YGGCRGNQNRFDTTQQ
VVGPCR A RFPRYYY NS S S KRCE KF I YG GCGGNANNFHTL E E
----- ------
CXQA-----
CJrRTCGGA
------
CLRICEPPQQTDKS
CVRACRPPERPGVC
CRETCGGK
CQGVCV
CEKVCGVRS
Fig. 29. Homologies among the amino acid sequences
of trypsin inhibitors A and B from Manduca
sexta and the Kuni tz class of trypsin inhi-bi tors. The conserved amino acid residues
have been boxed.
trypsin-like proteases, this residue, namely, Arg 15 is presumably the
specificity conferring residue in both inhibitors A and B, and the pep-
tide bond between Arg 15 and Ala 16 is the reactive site peptide bond
in these inhibitors.
Crystallographic studies (77) have shown that the BPTI molecule
has two B-pleated sheet regions, the first extends between amino acids
16 and 23 (BPS-I) and the second extends between residues 27 and 38
(BPS-II) . In addition, the BPTI molecule also has an a-helical struc-
ture within the carboxy terminus (between residues 46 and 56) and
another a-helix at the amino terminal section (between residues 2 and
7) . Our calculations based on Chou-Fasman algor ithms for predicting
the secondary structures in proteins were able to confirm these
observed secondary structures of BPTI.
A summary of the secondary structure predictions for inhibitors
A, inhibitor B, and BPTI using Chou-Fasrnn algor ithms is given in Table
A B-pleated sheet regions at positions corresponding to BPS-I could
be predicted in trypsin inhibitor A and in trypsin inhibitor B. Neither
inhibitor A nor inhibitor B were predicted to have the NH2-terminal 
helix present between residues 2 through 7 of BPTI. The region
corresponding to this a-helix was predicted to have a B -pleated sheet
structure in inhibitor A (residues -1 through 7), while inhibitor B was
predicted to have an unstructured region (residues 2 through 15). The
amino acid residues 45 through 54 of BPTI have been predicted to form
an a-helix, the cQrresponding region in inhibitor B (residues 45
through SO) was also predicted to form a-helix. Predictions of the
secondary structures beyond residue 30 (using BPTI enumeration, see
;--
Table 8
i:i Comparison of the secondary structure predictions forBPTI , trypsin inhibitor A , and trypsin inhibitor B
using Chou-Fasman calculations.
Predictions for
BPTI
Predictions for
Inhibi tor A
Predictions for
Inhibitor B
coil
17 to -
helix8 to -
helix pleated sheet coil
(2 to 7) 1 to 7) (2 to 15)
coil helix coil
(8 to 15) (8 to 13) (2 to 15)
pleated sheet pleated sheet pleated sheet
(16 to 23) (14 to 24) (16 to 24)
coil coil coil
(24 to 26) (25 to 30) (25 to 31)
pleated sheet plea ted sheet
(27 to 38) (32 to 40)
coil coil
(39 to 44) (41 to 44)
helix O'- helix
(45 to 54) (45 to 50)
The numbers , in parentheses denote the extent of each
prediction.
Prediction of secondary structures were not performed
for residues 31 to 39 of inhibitor A because this
sequence contains two undetermined amino acid residues.
** 
helix probably extends beyond residue 50 in inhibi-
tor B. The extent of this a-helix could not be fully
predicted due to the undetermined residue at position
52 and due to the lack of sequence data beyond residue 53.
rg-
Fig. 28) was not attempted for inhibitor A because the sequence 31-39
contains two unidentified amino acids (residues 31 and 38) and further,
the sequence of inhibitor A, at present, is not known beyond the
position corresponding to residue 39 of BPTI.
The effect of trypsin inhibitors A and B on the activation of
prophenoloxidase from a hemocyte lysate of Manduca sexta
It.
.t"
When crude hemolymph was treated with an equal volume of 0. 1% SDS,
phenoloxidase activity appeared after 10 minutes. However, if
diisopropylfluorophosphate (DFP, an inhibitor of serine proteases) at a
concentration of 0. 01 M was added to crude hemolymph prior to adding
SDS, phenoloxidase activity did not appear even after 30 minutes (Fig.
30) . This indicated that serine protease (s) are involved in the
activation of prophenoloxidase. Therefore, it was of interest to test
whether purified trypsin inhibitors A and B would affect the activation
of prophenoloxidase. A hemocyte lysate preparation was used to study
the effect of inhibitors A and B on prophenoloxidase activation,
because herncytes are generally considered to be the source of pro-
phenoloxidase (27).
Sonication of the hemocytes was observed to cause activation of
prophenoloxidase, but maximum phenoloxidase activity was obtained only
after incubating hemocyte lysates with laminarin and MgC12 for 1 hour
at room temperature (78). In this study inhibitors A and B were added
at a concentration of 8. M and 27. M, respectively, both during
sonication of the hemocytes and during the sUbsequent incubation of the
lysates with laminarin. The results given in Table 9 demonstrate that
addition of inhibitor A caused ca. 50% reduction in phenoloxidase
-=.
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y,:
500
400
300
200
100
-f. TIME (min.
Fig. 30 The effect of DFP on the appearance of phenol-
oxidase acti vi ty in SDS-treated hemolymph of
the larval stage Manduca sexta.
Phenoloxidase acti vi ty in the absence of DFP
Phenoloxidase activity in the presence of
o . 01 M DFP 
;1"
Table 9
The effect of trypsin inhibitors A and B on the
activation of prophenoloxidase in lysates of
Manduca sexta hemocytes.
Test system
No inhibitors(control)
Phenoloxidase acti vi ty
100
With inhibitor A (8.
With inhibitor B (27.
52*
110*
* % of control activity
1-.
acti vi ty . However, inhibitor B, even at three times the concentration
did not diminish the appearance of phenoloxidase activity.
Does the hemal h of Manduca sexta contain factors functionall
analo ous to human com lement factors Band IL.
ti, Although a complement system has not been unequivocally
demonstrated in insects, the general mechanism of activation of
'.".
prophenoloxidase in insect hemolymph by yeast zymosan or laminar 
in is
similar to the activation of the mammalian complement system via the
alternative pathway (21, 25). Since many key biochemical pathways are
evolutionally conserved, it was of interest to examine whether the
hemolymph of Manduca sexta could functionally substitute in hemolytic
assays for the factors Band D of the human alternative complement
pa thway .
Rabbit erythrocytes (RE) are natural activators for the altern-
ative complement pathway and are hemolysed when added to fresh or fresh
frozen serum. It was, therefore, of interest to investigate whether RE
could act as an activator for factors present in Manduca sexta
hemolymph. Incubation of RE with the hemolymph of Manduca sexta did
not result in hemolysis suggesting that a completely functional
alternative complement pathway leading to the lysis of rabbit
erythrocytes was absent in the hemolymph of Manduca 
sexta.
addition, components in crude hemolymph did not appear to substitute
for either factor B or factor D when assayed in sera deficient in
factors B (RB) and D (RD) (Table 10). At face value these results
suggested that proteases analogous to human factors 
Band D may not be
present in Manduca sexta hemolymph.
Interestingly, a heat labile
factor present in Manduca sexta hemolymph abrogates RE hemolysis when
Table 10
Experiments to assess the effects 
of' Manduca sextahemolymph and purified trypsin inhibitors A and B
on the activity of the human serum alternative
complement pathway.
;:-
Experimen t
Hemolys is
(% of control) 
RB serum + factor B
100
RB serum + 8 l hemolymph
RD serum + factor (functionally pure) 102
RD serum + 10 l hemolymph
RB serum + 25 l hemolymph +factor B
RB serum + factor B + 25 
boiled hemolymph
RB serum + factor B + inhibitor A(0. 43 nmoles)
RB serum + factor B + inhibitor B(1. 67 nmoles)
* Hemolysis by 25 1 of a 1: 3 dilution of RB serumreconsti tuted with g/ml of purified factor Bwas taken as 100%.
using RB serum reconstituted with purified human factor B (recon-
stitution of RB serum with 4 g/ml factor B fUlly restores the altern-
ative pathway complement activity). The observed inhibi tion 
hemolysis could be due to the inhibition of the function of one or more
alternative complement pathway components by hemolymph or to the non-
productive, non-lytic, fluid-phase proteolytic activation of factor B
by proteases present in the hemolymph. For that matter, the hemolymph
could be acting to inhibit the action of any of the complement proteins
D, B, properdin, or C3 to C9 by activating non-productively. The
addition of purified inhibitors A or B to the assay for the alternative
complement pathway had no effect (Table 10). The amount of inhibi tor A
and inhibitor B added were, on a molar basis, respectively, 10 fold and
40 fold in excess of the amount of factor B present in the assay
mixture. These results, therefore demonstrate that neither inhibitor A
nor inhibitor B were the factors present in hemolymph which inhibited
activation of the human alternative complement pathway.
To assess whether fluid phase cleavage of factor B did indeed
occur on addition of Manduca sexta hemolymph, fresh frozen human serum
and purified human factor B were each separately incubated with Manduca
sexta hemolymph and the extent of factor B cleavage was assessed by
immunoelectrophoresis (Fig. 31). Pur ified factor B was not cleaved by
the addition of Manduca sexta hemolymph, suggesting that the Manduca
sexta hemolymph does not contain proteases capable of cleaving human
factor B. By contrast, factor B cleavage fragment, Bb, was observed
when fresh frozen serum was incubated with Manduca sexta hemolymph
suggesting that the hemolymph stimulates the initial events in the
I,.:
'- 
Fig. 31 Schematic diagram depicting immunoelectropho-
retic assessment of human factor B 
cleavage.WeIl
Well 2
Fresh frozen serum incubated with hemolymph
Fresh frozen serum incubated with GVBS
Precipi tin band of uncleaved factor B
Precipi tin band of Bb fragment
11,
It.
ii,
activation of the alternative complement pathway but does not itself
provide a protease analogous to factor D which cleaves factor 
Furthermore, the factor (s) in hemolymph responsible for causing human
factor B cleavage is not likely to be non-specific stimulators such as
lipopolysacchar ides, laminar in or zymosan because heat inacti va ted
hemolymph did not cause cleavage of factor B in fresh frozen human
serum. Another distinct possibility is that the hemolymph may provide
a C3b-like cofactor which forms a stable fluid-phase complex with
factor B. Factor B thus complexed may be cleaved by factor 
If the
complex of the hemolymph factor and Bb is active as C3 conver tase, it
can form more C3b, which would combine with factor B and cause an
extensive cleavage of the latter factor (see Appendix on cobra venom
factor) . The observation that hemolymph causes factor B cleavage only
in serum and not purified factor B supports this contention.
In the
latter case, factor D is not present to cleave factor B in complex with
the hemolymph factor. Further, since the complex is present pr imar ily
in the fluid phase and not deposited on RE, hemolysis does not ensue
the activation of the complement pathway in a hemolytic assay in the
presence of Manduca sexta hemolymph.
CHAPTER IV
DISCUSSION
Com ar isons of the structures and erties of tr sin
inhibitors A and B from Manduca sexta with bovine
ancreatic tr sin inhibitor (BPTI)
Based on the observation that polypeptide protease inhibitors
form strong complexes with proteases, a relatively simple protocol for
the isolation of trypsin inhibitors from the hemolymph of the Manduca
sexta larvae was developed. At least two inhibitors present in the
hemolymph bound to immobilized trypsin and required 0. 1 M HCl contain-
ing 0. 75 M NaCl (pH 1. 5) for elution. The catalytic action of trypsin
is essential for the formation of BPTI-trypsin complex (79),
consequently the stability of the BPTI-trypsin complex is lowest at
acid pH when trypsin is catalytically not active. By analogy, the
stabili ty of the complexes between inhibitors A or B and trypsin should
be lower at acid pH. In view of the stability of inhibitors A and B at
acid pH, it was decided to use acid buffers for the elution of the
bound inhibitors from trypsin-Sepharose. However, approximately 50% of
:1'"
the total trypsin inhibitory activity in crude hemolymph was lost
following trypsin-Sepharose affinity chromatography. Elution with 0.
M HCl containing 1. 5 M NaCl or 0. 1 M ammnium acetate adjusted to pH
0 with glacial acetic acid did not improve the yield of trypsin
inhibitors A or B. Therefore, it appears that there may be yet other
trypsin inhibitory component (s) which are bound very tightly trypsin-
Sepharose. Further attempts to character ize this (these) component (s)
were not performed. Both inhibitor A and inhibitor B are stained
100
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weakly by coomassie br illiant blue G 250 or R 250 and amido black
suggesting that these inhibitors do not have strong binding sites for
these dyes. Since some glycoproteins also do not stain wi th the common
protein stains (80), trypsin inhibitors A and B were sUbsequently
tested for the p sence of carbohydrates. Neither inhibitor A nor
inhibitor B stained with Alcian blue or periodic acid-Schiff' s base
stains suggesting that they do not contain appreciable carbohydrate.
Trypsin inhibitors from Manduca sexta hemolymph share many of
the properties of BPTI. For example, inhibitors A and B, like BPTI,
are both heat and acid-stable and inhibit trypsin-like ser ine pro-
teases. A high proportion of secondary structure (S-pleated sheet) and
the presence of three intramolecular disulfide bonds are thought to be
responsible for the stability of the BPTI molecule (77). Since the
three half-cystine residues so far unambiguously identified in inhibitor
A and the five half-cystine residues thus far sequenced in inhibitor B
are found in corresponding positions in BPTI (Fig. 29), it is likely
that the stability conferred by these disulfide bonds also is present
in the Manduca sexta trypsin inhibitors. Moreover, the importance of
exposed disulfide bonds towards the structural stability of inhibitors
A and B is illustrated by the fact that reduction of either inhibitors
under relatively mild nondenaturing conditions (2. 5 mM DTT in 20 mM
tr is-HCl buffer, pH 7. 5) leads to the complete loss of biological
activity. By contrast, reduction of the exposed disulfide bond
(between Cys 14 and Cys 38) in BPTI by sodium borohydride (81) does not
affect BPTI activity. Clearly other intramolecular interactions in the
molecule apart from the Cys 14-Cys 38 disulfide bond provide for the
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integrity of the BPTI structure. It is, therefore, reasonable to
presume that some of the interactions which provide for the integrity
of the BPTI structure may not be present in inhibitors A and B.
In order to examine the possibility that inhibitor B (the lower
molecular weight inhibitor) was derived from inhibitor A by limited
proteolysis, each inhibitor was subjected to amino acid compositional
analysis (Table 7), and tryptic peptide maps of each protein were
prepared. The amino acid compositions are different and the tryptic
peptide map of each inhibitor is unique. Moreover, the NH2-terminal
amino acid sequences of inhibi tor A and B were different proving con-
clusively that each was a different protein. Nevertheless, close in-
spection of the amino acid sequences revealed that inhibitors A and B
were homologous proteins and share 18 out of the 38 commn residues
(Fig. 28).
Trypsin inhibitors A and B inhibit the activities of trypsin and
trypsin-like ser ine proteases (Table 6), but at picomolar concen-
trations of the proteases an order of magnitude more
of inhibitors A
and B are required for plasmin and thrombin inhibi tion than for trypsin
inhibi tion. Weinstein and Doolittle (82) have studied the hydrolysis
of a series of synthetic peptide and ester substrates by trypsin,
plasmin, and thrombin and have concluded that plasmin cleaves Lys-X
peptide bonds preferentially, while thrombin is selective for Arg-x
peptide bonds. Trypsin hydrolyses both Lys-X and Arg-X peptide bonds.
Trypsin inhibitors A and B both have Arg at the reactive site (Arg 15).
Therefore, it is understandable that a relatively Lys specific protease
like plasmin would have a lower affinity towards inhibitors A and B.
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Among trypsin, plasmin, and thrombin, the protease which shows the
highest selectivity is thrombin. Thrombin is selective for Arg-X
peptide bonds and cleaves only four Arg-Gly peptide bonds in its
natural substrate fibrinogen. It is noteworthy that BPTI which has
reactive site Lys (Lys 15) does not inhibit thrombin. Since both
inhibi tors A and B have Arg-Ala peptide bond at their presumed reactive
si tes, it is not unexpected that these inhibitors recognize and thus
inhibit thrombin. However, the peptide conformation around the re-
active site in inhibitors A and B may not be conducive for the rapid
interaction with thrombin as it is with trypsin. Consequently, trypsin
inhibitors A and B display lower affinity for thrombin than for
trypsin.
Interestingly, chymotrypsin is strongly inhibited by trypsin
inhibitors A and B although chYmtrypsin does not exhibit specificity
for basic amino acids. Elastase, however, is not inhibited by either
trypsin inhibitor A or trypsin inhibitor B. Trypsin, chYmtrypsin, and
elastase belong to the same family of pancreatic pro teases and the
acti ve site region of all the three proteases are similar. The speci-
ficity pocket of elastase can accommdate only small aliphatic side
chains and cannot accommodate the side chain of Arg 15 of inhibitors A
and B. Consequently, this protease cannot bind to trypsin inhibitors A
and B. By comparison, chYmtrypsin has a larger specificity pocket
which may accommdate larger side chains. Studies with molecular models
of chymotrypsin and BPTI have shown that Lys 15 of BPTI can be accom-
modated within the specificity pocket of chymotrypsin provided the pK
of the E-amino group of Lys is lowered or the positive charge on Lys 15
UK-
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is bur ied Moreover, the amino acid residues of trypsin which interact
with BPTI are conserved in chymotrypsin (83). Inhibitors A and Bare
homologous to BPTI (see below). By analogy to BPTI, it may be expected
that Arg 15 of inhibitors A and B will also be accommodated wi thin the
specificity pocket of chymotrypsin. Hence, trypsin inhibitors A and B
are able to inhibit chymotrypsin.
Neither trypsin inhibitor A nor trypsin inhibitor B inhibit pro-
teases from bacter ia or plants In fact, the bacter ial protease
subtilisin BPN' completely inactivates trypsin inhibitors A and B.
BPTI, by contrast, is not inactivated by subtilisin BPN' However,
like trypsin inhibitors A and B, BPTI also does not inhibit subtilisin
BPN' .
BPTI forms a 1:1 complex with both trypsin and chymotrypsin
(84) . Stoichiometric calculations (see page 71) based on molecular
weights of 15, 000 fpr inhibitor A and 24, 000 for both trypsin and
chymotrypsin demonstrates that trypsin inhibitor A likewise forms a 1: 
complex with trypsin as well as chymotrypsin. Inhibi tor A is a dimer
composed of two identical subunits; the formation of 1:1 molar com-
plexes with trypsin and chymotrypsin suggests that both the subunits
are needed for complex formation. However, it is also possible that
binding of a protease to a subunit renders the other subunit unavail-
able due to steric hindrance. As mentioned ear lier, stoichiometr ic
calculations and determination of Ki were not performed with inhibitor
B, because inhibitor B appears to have two components.
The calculated inhibitory constants, Ki values, for inhibitor A
interaction with try sin and chymotrypsin are 1. 45 x 10-8 M and 1. 7 x
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10-8 M respectively. Table 11 summarizes the Ki values for several
members of the BPTI family of trypsin inhibitors. Inhibitor A has six
orders of magnitude less affinity for trypsin than BPTI. When compared
to other trypsin inhibitors from lower animals, inhibitor A displays
approximately 1/100 the affinity for trypsin.
Inhibitor A forms a tight equimolar complex with trypsin which
is not dissociated by chymotrypsin. Similar ly, the chymotrypsin-
inhibi tor A complex cannot be displaced by free trypsin, which is in
agreement with their inhibition constants. Further, binding of one
protease to inhibi tor A precludes the binding of the other protease
thereby indicating that inhibitor A does not have independent binding
site for each protease. However, the present results do not indicate
whether trypsin and chymotrypsin bind to the same site on inhibitor 
or the binding sites of trypsin and chymotrypsin are close such that
binding of one protease sterically hinders the binding of the other
protease. X-ray crystallographic studies have shown that BPTI binds to
the active site region of trypsin (58). Molecular models based on the
crystal structure of chymotrypsin and the structure of BPTI (83) have
shown that BPTI can bind to the active site of chymotrypsin provided
the pK of the s-amino group of Lys 15 is lowered or the positive charge
on this residue is bur ied. Although inhibitors A and B have Arg 15 
instead of Lys 15, other structural features of inhibitors A and B
closely resemble that of BPTI (see below). Therefore, it is probable
that inhibitor A binds to chymotrypsin and trypsin in a manner similar
to BPTI.
Table 11
Representative inhibition constants (K.
) for trypsininhibition by trypsin inhibitors of th BPTI (Kunitz)family.
Inhibi tor React i ve K. (M) Reference
site (P
amino acid *
BPTI Lys 0 x
Manduca sexta (Arg 15) 45 xinhibi tor 
Cow colostrum Lys 0 xinhibi tor
Snai 1 iso- Lys 10 -9 inhibi tors
Sea anemone Arg 15 0 x -10inhibitor
Cuttlefish Arg 15 2 xisoinhibi tor L
Russell viper Arg 15
venom inhibitor
*Using BPTI enumeration
, see Fig. 29.
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Compar ison of the amino acid sequences of trypsin inhibitor A
and trypsin inhibitor B with that of BPTI (Kunitz) (Fig. 29) revealed
that these inhibitors are homologous to the latter protein. Before
examining the homology in detail, it is necessary to briefly review the
structure of BPTI. BPTI is a pear shaped molecule which is very com-
pact and rigid (77). The rigidity and the compactness are, in part,
attributable to the three disulfide bonds present in the molecule.
account of its small size, BPTI has only a small proportion of internal
residues. The aromatic residues Phe 4, Tyr 21, Phe 22, Tyr 23, Phe 33,
Tyr 35, and Phe 45 (see Fig. 3) are present inside the molecule and
are, therefore, important structural determinants. The side chain of
Asn 43, which is also present in the molecular interior, participates
in three crucial hydrogen bonds (with the carbonyl groups of Glu 7 and
Tyr 23 and the amino group of Tyr 23) in the center of the molecule
(85) . BPTI polypeptide chain folding requires that residues at posi-
tions 12 and 37 not have a side chain. Accordingly, Gly is present at
both of these positions.
Inhibitor A has an extra segment of 17 residues at its amino
terminus which is not present in BPTI. Consequently, it is possible to
compare only residues 18 through 56 of inhibitor A with BPTI. Inhi-
bitor B, on the other hand, does not have the extra amino terminal seg-
ment, and therefore, all 53 residues of inhibitor B thus far sequenced
can be compared with BPTI. A compar ison of the amino acid sequences of
trypsin inhibitors A and B with those of selected members of the BPTI
(Kunitz) family of trypsin inhibitors is given in Fig. 29. For the
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ease of comparisons, the numbering system used corresponds to that of
BPTI .
Half-cystine residues are, in general, invariant among the BPTI
family of trypsin inhibitors (85). The three half-cystine residues
unambiguously indentified in inhibitor A and the five half-cystine
residues thus far identified in inhibitor B are homologous to BPTI.
The internal aromatic residues Tyr 21, Tyr 23, Phe 33, and Tyr 35 are
clearly conserved in inhibitor A and inhibitor B. Phe 4 has been
replaced by Ile in both inhibitors A and B, however, since Ile is also
hydrophobic, this replacement is not expected to affect the local
interactions in that region. The conservation of Phe 45 and Asn 43 are
apparent in inhibitor B, but the lack of sequence data does not allow
the comparison of these residues in inhibitor The str ict conser va-
tion of Gly residues at 12 and 37 are evident in both inhibitor A and
in inhibitor B. The aromatic residue Phe 22 however, has been replaced
by Gly in inhibitor A and Ala in inhibitor 
A compar ison of the trypsin contact residues of BPTI wi th the
homologous sequences in inhibitor A and inhibitor B deserves attention.
In the BPTI molecule, the peptide segments extending from residue 12 to
18 and 35 to 39 are intimately involved in the contact with trypsin.
~e side chain of Lys 15 is inserted into the specificity pocket of
trypsin wi th the
€-amino group hydrogen bonded to the S-car boxyla te
of Asp-189 of trypsin. A compar ison of the amino acid residues at the
trypsin contact region of BPTI with homologous sequences of inhib-
i tor A and inhibitor B is presented in Fig. 32. Of the 12 residues
compared, six residues
, namely Gly 12, Cys 14, Ala 16, Tyr 35, Gly 36,
rc"
Res i due number 12 13 14 15 16 17 18 35 36 37 38 39
BPTI
Inhibi tor 
Inhi bi tor B
Fig. 32 Comparison of the trypsin binding region of
BPTI with the homologous regions of trypsininhibi tors A and B.
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and Gly 37, are conserved in inhibitor A. Lys 15 is conservatively
replaced by Arg in inhibitor A and the hydrophobic residue Ile 18 is
replaced by another hydrophobic residue Phe. Since half-cystine resi-
dues are conserved among the members of the BPTI (Kuni tz) family, it is
likely that the amino acid at position 38 of inhibitor A (Fig. 29)
a half-cystine residue. In trypsin inhibitor B, eight of the twelve
residues namely Gly 12, Pro 13, Cys 14, Ala 16, Tyr 35, Gly 36, Gly 37,
and Cys 38 are conserved compared to BPTI. As found for inhibitor A,
Lys 15 and Ile 18 are conservatively substituted by Arg 15 and Phe 18,
respectively, in inhibitor B.
The types of interactions between the contact regions of BPTI
and bovine trypsin are listed in Table From the table it is clear
that Lys 15 is a major contributor of polar (four hydrogen bonds) and
van der Waals interactions. Lys 15 of BPTI has been replaced by Arg in
both inhibitors A and B. Since Arg is also a basic amino acid, it may
be expected to enter into similar interactions as Lys 15 of BPTI.
Two residues at the trypsin contact region which are strikingly
different in trypsin inhibitors A and B from those of BPTI are Arg 17
and Arg 39. Arg 17 is replaced by Leu in inhibi tor A and Gly in inhib-
itor B, while Arg 39 is replaced by GIn in both inhibitors A and B.
Blow et ale (83) have noted that BPTI makes about 217 van der Waals
contacts with trypsin and, of these . 60% (135 contacts) are contri-
buted by Arg 17 and Arg 39. The absence of both of these residues from
inhibi tor A and inhibitor B may explain the lower Ki which was found,
at least in the case of inhibitor A to be 10-8 M vs Ki for trypsin-BPTI
interaction which is 10-14 M (55). In addition, Pro 13 is replaced by
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Val in inhibitor A. The side chain of Pro 13 of BPTI does not enter
into critical interactions with trypsin, therefore the replacement of
Pro by Val may not affect the binding of inhibitor A to trypsin.
A compar ison of the secondary structure predictions of inhibi tor
A, inhibitor B, and BPTI using Chou-Fasman calculations are tabulated
in Table 8. Perusal through this table shows that the secondary struc-
ture predictions for inhibitor B is similar to that of BPTI, with the
exception that the amino terminal a-helix of BPTI is replaced by a ran-
dam coil. Compar ison of the secondary structure predictions of in-
hibitor A with BPTI revealed that there are some similarities and some
differences between these two proteins. The amino acid residues of in-
hibi tor A from Ala 16 to Asp 24 was predicted to assume pleated
sheet structure. This would correspond to the B-pleated sheet struc-
ture BPS-I (between Ala 16 and Tyr 23) of BPTI.
~e amino acid sequences of inhibitor A (from Tyr -1 to Leu 
was predicted to nucleate a B-pleated sheet, whereas the corresponding
region in BPTI harbors an a-helix. Further, an a-helix was predicted
from ' Pro 8 to Val 13 of inhibitor A. By contrast, the sequence corres-
ponding to this a-helix of inhibitor A was predicted to be a random
coil in BPTI. Pro residues, in general, disrupt both a-helix and
pleated sheet structures in proteins. The absence of Pro 9 and Pro 13
in inhibitor A (but which are present in BPTI) may facilitate the
nucleation of a-helix between Pro 8 and Val 13. An a-helix was pre-
dicted within the unique amino terminal peptide sequence of inhibitor A
(between Val -2 and Ile -8).
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The amino terminal region of inhibitor A appears to be highly
structured with alternate a.-helical and pleated sheet regions. One
may speculate that this conformation may be necessary for the efficient
interaction of inhibitor A with its unique target protease in the hemo-
lymph.
It was pointed out earlier (page 108) that most of the critical
residues essential for the folded conformation of BPTI are conserved in
inhibi tors A and B. This observation together with the finding that
the secondary structure of inhibitor B closely resembles that of BPTI
indicates that the conformation of at least inhibitor B, and probably
the region of inhibitor A homologous to BPTI as well, resembles that of
BPTI . Further, the conservation of the amino acid residues in trypsin
inhibitors A and B at positions homologous to the trypsin binding re-
gion of BPTI indicate that trypsin inhibitors A and B probably interact
wi th trypsin in a manner analogous to BPTI.
The possible biological significance of trypsin inhibitors A and B
from Manduca sexta hemolymph
It was pointed out in the introduction section that
. a number 
physiological processes in insects such as tissue turnover dur ing meta-
morphosis, activation of hemolymph prophenoloxidase, and coagulation
require the action of proteolytic enzymes. Some of these processes may
involve several proteases participating in a cascade. The proteolytic
activation of hemolymph prophenoloxidase, for example, has been sugges-
ted to resemble the initial events in the activation of the human com-
plement alternative pathway (21, see also section C below). Efficient
control mechanisms should exist for the regulation of hemolymph pro-
- '
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teases. The presence of a large amount of protease inhibitors in the
hemolymph of all insects examined suggest that these inhibitors are
important in the regulation of proteases in these animals.
Three lines of evidences suggest that trypsin inhibitors in Man-
duca sexta hemolymph may be important in regulating the activity of
hemocyte and hemolymph prophenoloxidase. First, spontaneous activation
of hemolymph prophenoloxidase vitro is slower in the larval hemo-
lymph than in the the pupal hemolymph, and this activity is inversely
related to the amount of trypsin inhibitory acti vi ty (cf. Fig. 7).
Second, the prophenoloxidase activating enzyme of a closely related
species Bomb mor i has been pur ified and has been shown to be a ser ine
protease with trypsin-like specificity (19). Partial purification of a
prophenoloxidase activating enzyme from Manduca sexta has also been
achieved and this enzyme also appears to be a serine protease with try-
psin-like specificity. Since both inhibitors A and B are trypsin inhi-
bitors, it is not unreasonable that these inhibitors could control the
acti vi ty of this prophenoloxidase acti va ting enzyme. Finally, studies
reported here have shown that addition of purified inhibitor A to a
hemocyte lysate decreased the rate of appearance of phenoloxidase acti-
vi ty (Table 9). Interestingly, inhibitor B, even at three times the
concentration of inhibitor A, did not affect the activation of pro-
phenoloxidase suggesting that inhibitor A is involved in the control of
prophenoloxidase activation while inhibitor B may
, not be important.
Although the exact reason for this selectivity is not immediately
obvious, it is reasonable to assume that the selectivity is related to
the structure of these inhibitors. The amino terminus of inhibi tor A
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has l8 additional residues not found in inhibitor B (see Fig. 28) nor
BPTI or other known trypsin inhibitors of the BPTI (Kuni tz) class for
that matter. The extra amino acid residues may be involved in the
selective recognition and therefore the inhibition of one or more pro-
teases involved in prophenoloxidase activation.
Dur ing the pupal stage, insect tissues undergo extensive turn-
over and proteolytic enzymes playa key role in this process (7). Pro-
tease inhibitors have been implicated in the control of metamorphosis-
associated tissue proteolysis (46). The decreased acti vi ty of the
trypsin inhibitors observed in the pupal stage in contrast to the
larval stage is consistent with this hypothesis. It is not known if
the decreased activity of the trypsin inhibitors is due to a lower
biosynthetic rate or to the inhibitors being preferentially catabolized
during the pupal stage so that they do not interfere with tissue
proteolysis. The pos ibility that the hemolymph trypsin inhibitors
could be taken up by the surrounding tissues and regulate intracellular
proteolysis cannot be excluded. Further studies on the isolated
proteases involved in tissue catabolism dur ing metamorphosis and the
effect of hemolymph protease inhibitors on these proteases will
obviously be important in understanding the various control events
during metamorphosis.
Apart from Manduca sexta, protease inhibitors homologous to BPTI
have been isolated from such diverse sources as humans (86), snake
venom (87), cuttlefish (88), and sea anemone (89). The gene coding for
the BPTI (Kunitz) class of protease inhibitors thus appears to be very
old and well distributed in the animal kingdom. The high degree of
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amino acid sequence homology among the diverse members of the BPTI
(Kunitz) family of protease inhibitors (for example see Fig. 29) demon-
strates that this family evolved from a common ancestor very early in
evolution.
The gene coding for BPTI (Kunitz) class of protease inhibitors
appears to have been retained' by primitive as well as more evolved
animals, suggesting that these gene products serve important
function (s) in the organism. Although the precise physiological
functions of this group of proteins is not clear, their commn property
as protease inhibitors suggests some functions in commn. Accord ing ly ,
our studies have indicated that Manduca sexta trypsin inhibitor A
probably plays a role in the regulation of the proteolytic activation
of prophenoloxidase in Manduca sexta hemocyte lysate (see page 92).
A discussion on the homology among the Manduca sexta trypsin
inhibitors A and Band BPTI (Kunitz) was presented earlier (pages 108
to 112). ~e BPTI molecule has a very compact and rigid conformation
which will not accommdate the addition or deletion of amino acid res 
dues (85). Consequently none of the BPTI (Kunitz) class of protease
inhibitors show any deletion or addition of amino acid sequences within
the BPTI (Kunitz) domain. The amino acid sequences of inhibitor A and
inhibitor B obtained thus far also suggest that there may be no
insertions or deletions within the BPTI (Kunitz) domain of these
inhibitors.
As a general rule, during the divergent evolution of a family of
proteins, the region of the polypeptide which defines the active site
is conserved even though other regions of the pOlypeptide may undergo
116
considerable change (92). In accordance with this rule, most of the
amino acid residues at positions homologous to the trypsin binding
regions of BPTI (residues 12 - 18 and 35 - 39) are either conserved or
conservatively substituted in inhibitor A and inhibitor B (page 108).
Striking conservation of certain residues in the sequence presented in
Fig. 29 pinpoints those residues crucial for maintaining the folded
can for ma t ion. Although the amino acid sequence data is not complete,
compar isons of the available amino acid sequences show that many
critical residues are conserved in both inhibitors A and Hence,
these inhibitors may be expected to assume a three dimensional struc-
ture similar to that of BPTI.
As alluded to earlier, inhibitor A has 17 additional amino acid
residues at the amino terminus when compared to BPTI. These amino
acid residues are clearly not critical for the protease inhibitory
function, because inhibitor B, which does not possess these residues,
and inhibitor A show similar inhibitory specificities towards various
proteases. It is, however, possible that these additional amino
terminal residues may be involved in the biological function of inhib-
itor A or, alternatively, may serve to modulate the affinity of inhib-
i tor A towards proteases. For example, only inhibitor A appears to
inhibit the activation of prophenoloxidase from hemocyte lysates of
Manduca sexta.
In many organisms, the BPTI (Kuni tz) family of protease inhib-
itors are present in multiple forms which differ slightly in their
pr imary structure. For instance, from snails twelve homologous inhib-
itors of the BPTI (Kunitz) class have been identified (90), and sea
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anemone has been shown to possess least ten homologous BPTI-like
trypsin inhibitors (89). Similar ly, this work has been demon-
strated that the hemolymph of Manduca sexta contains at least two homo-
logous trypsin inhibitors, namely inhibitor A and inhibi tor The
strong amino acid sequence homology between inhibitor A and inhibitor
indicate that these inhibitors probably arose by gene duplication and
subsequent diversification. The requirement for more than one form of
inhibi tor is not entirely clear; perhaps inhibitors with slightly
different specificities and/or kinetic properties may be required to
regulate the acti vi ty of proteases in different tissues.
Is there a s stem in Manduca sexta which resembles the
vertebrate alternative com lement athwa
The vertebrate complement system is both an amplifier of
specific immunity and a nonspecific effector of immune reactions (see
Appendix for a descr iption of the human complement system). A complete
vertebrate type complement system has not yet been demonstrated in
insects, nevertheless, a cobra-venom dependent " lytic complement-like
system" capable of hemolyzing sheep erythrocytes has been shown to be
present in the hemolymph of more primitive animals such as the horse-
shoe crab, Limulus hemus (93), and in the coelomic fluid of the
sea urchin Stron locentrotus droebachiensis (94) and the star fish
Asterius forbesi (93). Furthermore, known activators of the alterna-
tive pathway of complement such as fungal polysaccharides, yeast
zymosan and laminar in also induce the activation of prophenoloxidase in
insect hemolymph (21) and in the hemolymph of more primitive arthropods
such as the horse-shoe crab (78) and the crayfish (95). In all these
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cases these activators appear to activate one or more protease (s) which
in turn activate the prophenoloxidase. Thus, activation of prophe-
noloxidase is analogous to the early sequence of events involved in the
activation of the alternative complement pathway (see Appendix) .
Consequently, it was of interest to examine Manduca sexta hemolymph for
the presence of complement-like factors. Interestingly, factor (s) in
Manduca sexta hemolymph was observed to inhibit alternative complement
pathway-mediated hemolysis of rabbit erythrocytes. Since trypsin inhi-
bi tor A appear s to be involved in the regulation of prophenoloxidase
activation in Manduca sexta, it was initially decided to examine
whether inhibitor A and/or B also inhibit the proteolytic activation of
the human alter na t i ve complemen t pa thway Exper iments were also
performed to ascertain whether factors present in Manduca sexta hemo-
lymph could directly substitute for human complement factors Band D in
a rabbit erythrocyte hemolytic assay. These studies (page 94) indi-
cated that neither inhibitor A nor inhibitor B prevented activation of
the alternative complement pathway in human serum when examined in a
rabbi t erythrocyte hemolytic assay. Moreover, our studies also suggest
that crude hemolymph does not functionally substitute for alternative
complement factors Band D in the rabbit erythrocyte hemolytic assay.
Cruz and Day have identified protein factor (s) in the hemo-
lymph of the silkworm Bombyx mari (96) and the armyworm Spodoptera
frugiperta (97) which inhibit (s) the alternative complement pathway-
mediated hemolysis of rabbit erythrocytes. The mechanism of action of
these irihibitors have not been elucidated, but the authors suggest that
these factors may either block the C3b receptor or acceptor sites on
!L.
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rabbi t erythrocytes or could compete with C3 for the C3 convertase.
Koch and Nielsen (98) have demonstrated that addition of hemolymph of
the snail Helix pomatia causes the cleavage of factor B in human serum
and have suggested that a factor analogous to cobra venom factor (see
Appendix) may be present in Helix pomatia hemolymph. These authors,
however, have not determined whether the snail factor inhibits the
alternative complement pathway mediated hemolysis of rabbit erythro-
cytes .
Several mechanisms may be suggested for the observed inhibition
of the alternative complement pathway mediated hemolysis of rabbit
erythrocytes caused by Manduca sexta hemolymph.
First, the hemolymph
may contain C3b-like (cobra venom factor-like) factor (s) which bind (s)
to human factor B and causes its cleavage, thereby rendar 
ing it
unavailable to participate in the lysis of rabbit erythrocytes.
Secondly, hemolymph may contain protease (s) which directly cleave
factor B nonproductively and thereby prevent hemolysis by the late
acting complement components.
Third, factors analogous to H (which
causes the dissociation of the C3 convertase C3bBb) or C3b inactivator
(which proteolytically inactivates C3b) may exist in the hemolymph.
Finally, hemolymph may contain inhibitors that are able to inhibit the
activity of complement protease (s) . As preliminary exper iments to
distinguish among these mechanisms, we tested whether Manduca sexta
hemolymph contained factors capable of causing human factor B cleavage.
In this experiment, fresh frozen human serum was incubated with crude
hemolymph and factor B cleavage assessed by immunoelectrophoresis (page
97) . The results demonstrated that factor (s) present in crude hemo-
lymph induced
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the cleavage of human serum complement component factor B into Ba and
Bb fragments. Hemolymph, however, does not cleave purified factor B
indicating that hemolymph does not contain non-specific protease (5)
capable of cleaving factor B directly. The cleavage of factor B in
serum but not purified factor B by crude hemolymph suggests that factor
B probably must be complexed to C3b to be cleaved by the hemolymph
factor. A factor similar to factor D will cleave factor B in the serum
but not purified factor B. However, the hemolymph factor is not likely
to be factor D-like because such a factor would enhance rather than
inhibit hemolysis of rabbit erythrocytes in a hemolytic assay. The
hemolymph factor stimulating factor B cleavage is unlikely to be a non-
ecific stimulator such as a polysaccharide since boiling destroys the
abili ty of the hemolymph to induce factor B cleavage.
Taken together these findings are consistent with the working
hypothesis that Manduca sexta hemolymph contains a factor or factors
which cause (s) the cleavage of human complement factor B in complex
with C3b. The identity of this factor is not clear. However, the pre-
sence of a C3b-like factor in the hemolymph is a possibility. Such a
factor would cause factor D mediated cleavage of factor B by forming a
complex with the latter factor (see Appendix on cobra venom factor).
Furthermore, a C3b-like factor which is not affected by regulatory pro-
teins such as SIH and C3b inactivator can stimulate autocatalytic
depletion of C3 and thereby inhibit complement mediated hemolysis of
rabbit erythrocytes.
The present studies on the effect of Manduca sexta hemolymph on
the human alternative complement pathway are in accordance with the
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findings of both D' cruz and Day (96, 97) and Koch and Nielsen (98).
have demonstrated that Manduca sexta hemolymph causes both cleavage of
human serum complement factor B and inhibition of the alternative com-
p1ement pathway mediated hemolysis of rabbit erythrocytes. Our f ind-
ings suggest that insect hemolymph (and perhaps invertebrate hemolymph
in general) contains factor (s) which can initiate the vertebrate alter-
native complement pathway, but which does not cause hemolysis of rabbit
erythrocytes.
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APPENDIX
A short note on the human complement system
The human complement system consists of at least 20 blood plasma
proteins (Table 12), whose major function is to act as an effector
mechanism in immune defense against infection by microorganisms.
activation, the complement system causes the lysis of cellular antigens,
attracts phagocytic cells to the site of activation and promotes
phagocytosis. The initial steps in the activation of the complement
system occurs by two pathways, namely the classical pathway and the
alternative pathway. The classical pathway is activated mainly by the
formation of specific antigen-antibody complexes, whereas the altern-
ative pathway is activated by a variety of activators including poly-
sacchar ides, such as those present in bacter ial cell walls. Figure 33
is a diagram of the activation scheme of both pathways of complement.
The activation of complement by either pathway results in the formation
of two complex proteases, namely the C3 convertase and the C5 con-
vertase. The composition of the C3 convertase and the CS convertase is
different in each pathway, nevertheless, they catalyze identical
reactions. In both pathways, activation of CS is the last proteolytic
step and the product C5b associates with C6, C7, C8, and C9 to form the
lytic complex.
The initiation of the alternative complement pathway
The proteins involved in the initiation of the alternative path-
way are C3, factor B, and factor D. The mechanism of stimulation and
activation of the alternative complement pathway is still not clear.
Table 12
Proteins of the human complement system
!!'-
Proteins of the classical pathway of complement
Clq
Clr
CIs
Proteins of the alternative pathway of complement
Factor 
Factor B
Properdin
Proteins involved in membrane attack
Control proteins
inhibitor
C3b inact i va tor
J31H
C4b binding protein
DAF (decay acceleration factor)
CR-l (C3b receptor)
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The favoured mechanism involves the formation of the complex C3bB from
low levels of C3b present in the serum. When complexedwi th C3b, factor
B is cleaved by factor D into 63, 000 dalton Bb and 30, 000 dalton Ba
fragments. The Bb stays associated with C3b and forms C3 convertase.
The end product of C3 convertase, namely C3b, can then associate with
C3bBb to form C3b Bb, a C5 convertase. In addition, C3b also associates
wi th factor B molecules and generates more C3 convertase, thus ampli-
fying the alternative complement pathway. The C3bBb complex is rela-
tively unstable, but, binding to another serum protein, properdin,
extends the half-life of the complex. Inactivation of C3b is achieved
by a serum protease, C3b inactivator, which cleaves C3b in the presence
of another serum protein SlH. Particles with repeating units, such as
bacterial cell walls, afford microenvironments which protect C3b
against rapid destruction by C3b inactivator. Hence, these particles
serve to activate the alternative complement pathway.
Mechanism of action of cobra venom factor
A factor isolated from the venom of cobra (Na naja) is func-
tionally analogous to C3b but is resistant to inactivation by C3b
inactivator. Cobra venom factor, therefore, forms a stable C3 con-
vertase which catalyses the cleavage of C3 to C3b, and C3b in turn forms
more C3 conver tase . Through this autocatalytic mechanism C3 is quickly
depleted. Without C3 the entire complement system is ineffective.
I!'
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